ofloxacin profile

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4583
CHEMBL ID	4
CHEBI ID	7731
CHEBI ID	194135
SCHEMBL ID	24373
SCHEMBL ID	14163982
MeSH ID	M0023430

Synonym
ofloxacin otic
floxin in dextrose 5%
ccris 5233
ofloxacinum [latin]
dl 8280
ofloxacine
oxaldin
ofloxacino [spanish]
brn 3657947
ofloxacine [french]
(+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-
floxin in dextrose 5% in plastic container
orf 18489
ofloxacina [dcit]
visiren
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-
oflocet
pt 01
MLS001074203
bdbm50045004
HMS3393K06
AB00052263-13
AB00052263-12
BRD-A24228527-001-05-9
DIVK1C_000721
KBIO1_000721
exocine
hoe-280
wp-0405
tarivid
floxin otic
MLS000028749 ,
smr000058192
EU-0100904
ofloxacin, fluoroquinolone antibiotic
SPECTRUM_001186
OPREA1_242882
NCGC00178284-02
NCGC00178284-01
PRESTWICK2_000237
SPECTRUM5_001063
IDI1_000721
BSPBIO_003117
LOPAC0_000904
hoe 280
(+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
floxin
zanocin
ofx
dl-8280
oflx
ocuflox
exocin
AB00513820
C07321
82419-36-1
ofloxacin
8-fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-oxa-3a-aza-phenalene-5-carboxylic acid
DB01165
ofloxacin (jp17/usp/inn)
D00453
floxin (tn)
NCGC00094219-04
NCGC00094219-03
NCGC00094219-02
NCGC00094219-05
KBIO3_002617
KBIOSS_001666
KBIOGR_000667
KBIO2_006802
KBIO2_004234
KBIO2_001666
SPBIO_002234
SPECTRUM4_000324
SPBIO_001387
SPECTRUM2_001464
SPECTRUM3_001499
PRESTWICK1_000237
PRESTWICK0_000237
NINDS_000721
SPECTRUM1502044
PRESTWICK3_000237
BSPBIO_000313
nsc-727071
(+/-)-floxin
nsc727071
(+/-)-9-fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic acid
BPBIO1_000345
NCGC00094219-01
NCGC00094219-06
dl8280
STK256723
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
NCGC00015772-02
O 8757 ,
ofloxacine; dl-8280; hoe-280
HMS2092B10
AC-7616
HMS2090F07
NCGC00015772-10
CHEMBL4 ,
j01ma01
nsc-758178
HMS502E03
ofloxacino
ofloxacinum
CHEBI:7731 ,
HMS1921H12
HMS1568P15
CHEBI:194135
AKOS001033517
HMS2095P15
HMS3262F10
HMS3259G07
unii-a4p49jaz9h
(+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
ofloxacin [usan:usp:inn:ban:jan]
hsdb 8030
nsc 758178
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
nsc 727071
a4p49jaz9h ,
BBL005605
nsc758178
pharmakon1600-01502044
tox21_110703
dtxcid1021085
dtxsid3041085 ,
ofloxacina
HMS2235C05
CCG-39210
NCGC00015772-07
NCGC00015772-03
NCGC00015772-09
NCGC00015772-04
NCGC00015772-05
NCGC00015772-06
NCGC00015772-08
BCP9000851
floxil
flobacin
FT-0670773
FT-0673216
F0472-0226
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
FT-0630905
FT-0627808
NCGC00015772-13
LP00904
EPITOPE ID:116889
S1463
HMS3369B01
F0020-0095
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acid, dl-
ofloxacin [who-dd]
ofloxacin [usp-rs]
ofloxacin [jan]
ofloxacin [inn]
ofloxacin [mart.]
ofloxacin [ep monograph]
ofloxacin [usan]
ofloxacin [vandf]
ofloxacin [usp monograph]
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)-
ofloxacin [orange book]
ofloxacin [mi]
HY-B0125
CS-1891
9-fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
NC00466
O0403
AKOS016042783
SCHEMBL24373
NCGC00015772-12
tox21_110703_1
KS-5011
SCHEMBL14163982
NCGC00261589-01
ofloxacin, antibiotic for culture media use only
tox21_500904
O-2800
9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido [1,2,3-de]-1,4-benzoxazin-6-carboxylic acid
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
MLS006011774
9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
HMS3604B17
OPERA_ID_1114
AB00052263_14
AB00052263_15
mfcd00226105
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
VU0243192-7
(+/-)-9-fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
SR-01000076050-1
sr-01000076050
ofloxacin, vetranal(tm), analytical standard
ofloxacin, united states pharmacopeia (usp) reference standard
ofloxacin, pharmaceutical secondary standard; certified reference material
ofloxacin, european pharmacopoeia (ep) reference standard
83380-47-6
SR-01000076050-4
SR-01000076050-7
SBI-0050879.P003
HMS3712P15
rkl10083
Z56761309
(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1;(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1
BCP22048
(s)-ofloxacin;levaquin;quixin
Q411447
dl-ofloxacin
monoflocet
ofloxacin (floxin)
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic acid
ofloxacin,(s)
ofloxacin 100 microg/ml in acetonitrile
BCP14346
8-methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid
AMY22220
BRD-A24228527-001-19-0
SDCCGSBI-0050879.P004
NCGC00015772-22
SY007392
gtpl10918
exocin (eye drops)
SR-01000076050-16
A864414
7-chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylicacid
EN300-06482
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
1ST5740
SY052697
olfoxacin otic soln
ofloxaxin
ofloxacin ophth soln
ofloxacin (mart.)
ofloxacin (usp monograph)
ofloxacin (usan:usp:inn:ban:jan)
(3rs)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acid
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-(1,4)oxazino(2,3,4-ij)quinoline-6-carboxylic acid
s01ae01
ofloxacin ophthalmic
ofloxacinum (latin)
ofloxacin (usp-rs)
(+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7--oxo-7h-pyrido(1,2,3-de)--1,4-benzoxazine-6-carboxylic acid
ofloxacin (ep monograph)
s02aa16

Excerpt	Reference
"Ofloxacin is an antibiotic that binds to DNA complexes and type II topoisomerase, causing double-stranded breaks in bacterial chromosomes."	( Hamauzu, R; Hosaka, T; Hoshino, K; Kodani, S; Nakagawa, H, 2022)
"Ofloxacin (OFL) is a broad-spectrum fluoroquinolone antibiotic frequently used in clinic for treating bacterial infections. "	( Debognies, A; Deng, Y; Lu, T; Qian, H; Sun, L; Zhang, J; Zhang, Q; Zhang, Z; Zhou, Z, 2022)
"Ofloxacin (OFL) is a highly toxic antibiotic pollutant, and there are few reports on the effects of changes in OFL levels on tomato chlorophyll fluorescence parameters."	( Cao, B; Huang, T; Li, N; Li, P; Liu, S; Liu, X; Xu, K; Zhang, Y; Zhang, Z, 2023)
"Ofloxacin (OFLX) is a racemic mixture of levofloxacin which revealed phototoxicity in patients exposed with sunlight after medication. "	( Amar, SK; Dwivedi, A; Kushwaha, HN; Mujtaba, SF; Pant, MC; Ray, RS; Singh, SK; Yadav, N, 2014)
"Ofloxacin is an antimicrobial agent frequently found in significant concentrations in wastewater and surface water. "	( Guimarães, JR; Maniero, MG; Peres, MS, 2015)
"Ofloxacin is a synthetic antibiotic of the fluoroquinolone class, with activity against gram-positive and gram-negative bacteria. "	( Agubata, CO; Nzekwe, IT; Obitte, NC; Okereke, C; Onoja, RI, 2016)
"Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. "	( Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X, 2016)
"Ofloxacin, a quinolone, is an extensively used, well-tolerated antibacterial agent but has been reported to induce photosensitivity at low incidences. "	( Kaur, R; Rampal, S; Sethi, R; Singh, O; Sood, N, 2008)
"Antofloxacin hydrochloride is a new fluoroquinolone antibiotic with broad-spectrum in vitro activity. "	( Xiao, XM; Xiao, YH, 2008)
"Levofloxacin seems to be a good alternative treatment for patients with uncomplicated spontaneous ascites infections."	( Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T, 2010)
"Levofloxacin is a synthetic fluoroquinolone with a broad spectrum of antibacterial activity. "	( Burke-Fraga, V; Cariño, L; Fuentes-Fuentes, E; Galan-Herrera, JF; Namur, S; Parra, MG; Poo, JL; Rosales-Sanchez, O, 2009)
"Levofloxacin is a fluoroquinolone that has a broad spectrum of activity against several causative bacterial pathogens of community-acquired pneumonia (CAP). "	( Elkhatib, WF; Noreddin, AM, 2010)
"Antofloxacin hydrochloride is an effective and well-tolerated new fluoroquinolone that demonstrates clinical and bacteriological efficacies similar to levofloxacin for the treatment of AECB and AP."	( Bai, C; Huang, W; Mei, C; Wang, J; Xiao, Y; Xiu, Q; Xu, N; Zheng, Q, 2010)
"Levofloxacin is a fluoroquinolone used globally to treat respiratory, skin, and genitourinary tract infections. "	( Figueira-Coelho, J; Mendonça, P; Neta, J; Neves-Costa, J; Pereira, O; Picado, B, 2010)
"Levofloxacin n-oxide is an impurity isolated from levofloxacin."	( Guo, M; Li, J; Li, T; Wang, W; Zhang, X; Zhu, Q, 2012)
"Levofloxacin is a third-generation fluorinated quinolone antibiotic, is the active levo stereoisomer of ofloxacin, and has one of the most favorable adverse reaction profiles."	( Dortdudak, S; Eroglu, E; Kocyigit, I; Oymak, O; Sipahioglu, M; Tokgoz, B; Unal, A; Utas, C; Yucel, HE, 2012)
"Levofloxacin is a valuable antimicrobial agent and an optimal treatment option for AECB, CAP (as a monotherapy) and HAP (as combination therapy at a high-dose regimen). "	( Liapikou, A; Torres, A, 2012)
"Levofloxacin is a broad-spectrum antibiotic that exists as a hemihydrate under ambient conditions. "	( Gorman, EM; Munson, EJ; Samas, B, 2012)
"Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis. "	( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012)
"Levofloxacin is a third-generation fluoroquinolone with a broad spectrum of antibacterial activity, comprising enterobacteria, non-fermenters, Gram-positive cocci and some anaerobic species. "	( Geiss, HK; Hoppe-Tichy, T; Klee, F; Oberdorfer, K; Swoboda, S; von Baum, H, 2003)
"Levofloxacin is a recently introduced fluoroquinolone."	( Aros, C; Flores, C; Mezzano, S, 2002)
"Levofloxacin is a fluoroquinolone antibiotic commonly used to treat respiratory, urinary tract, skin and soft-tissue infections. "	( Lee, CH; Schwalm, JD, 2003)
"Ofloxacin is a fluoroquinolone antibacterial with potent bactericidal activities and the topical otological preparation of this drug has been clinically utilised since the late 1980s. "	( Tong, MC; Wai, TK, 2003)
"Ofloxacin is a quinolone administered to patients with severe infections. "	( El Menyawi, I; Fuhrmann, V; Mittermayer, C; Ratheiser, K; Schenk, P; Thalhammer, F, 2003)
"Levofloxacin is a new, recently commercialized fluoroquinolone. "	( Arnau, JM; Campany, D; Castells, X; Rigau, D; Vallano, A, 2003)
"Levofloxacin is a recent fluoroquinolone and its muscular toxicity is not well documented."	( Debien, B; Nadaud, J; Olive, F; Pats, B; Perez, JP; Petitjeans, F; Villevieille, T, 2003)
"Levofloxacin (Levaquin) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens. "	( Croom, KF; Goa, KL, 2003)
"Levofloxacin is a broad-spectrum antibacterial agent with activity against a range of Gram-positive and Gram-negative bacteria and atypical organisms. "	( Croom, KF; Goa, KL, 2003)
"Levofloxacine is a fluoroquinolone presenting good anti-pneumococcal activity, including against strains with reduced sensitivity to penicillin. "	( Bru, JP; Leophonte, P; Veyssier, P, 2003)
"Levofloxacin is a broad-spectrum fluoroquinolone antibiotic with activity against many pathogens that cause bacterial infections in children, including penicillin-resistant pneumococci. "	( Blumer, JL; Bocchini, JA; Bradley, JS; Chien, S; Kearns, GL; Maldonado, S; Natarajan, J; Noel, GJ; Wells, TG, 2005)
"Levofloxacin (LEV) is a fluoroquinolone antimicrobial agent. "	( Cai, Z; He, Y; Song, G, 2004)
"Levofloxacin is a fluoroquinolone antimicrobial agent for which pharmacodynamic relationships between the maximum serum antibiotic concentration (Cmax)/minimum inhibitory concentration (MIC) ratio and/or the area under the serum concentration-time curve during a 24-h dosing period (AUC(0-24))/MIC ratio and clinical and/or microbiological outcomes have been developed. "	( Blasi, F; Cazzola, M; Donnarumma, G; Marchetti, F; Matera, MG; Sanduzzi, A; Tufano, MA, 2005)
"Ofloxacin is a fluoroquinolone agent available as an immediate-release (IR) tablet formulation administered twice daily. "	( Badri, N; Di Spirito, M; DiMarco, M; Ducharme, MP; Marier, JF; Monif, T; Morelli, G; Rampal, A; Tippabhotla, SK, 2006)
"Levofloxacin is a fluoroquinolone with extensive renal elimination and enhanced penetration into lungs and Pseudomonas aeruginosa (PA) biofilms."	( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007)
"Antofloxacin hydrochloride is a newly developed fluoroquinolone antibacterial in China, which has comparable in vitro and animal pharmacological and toxicological properties to levofloxacin and is worthy of further clinical trial. "	( Kang, Z; Li, T; Liu, Y; Lu, Y; Xiao, Y; Zhang, M, 2008)
"Levofloxacin (Levaquin) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin. "	( Anderson, VR; Perry, CM, 2008)
"Ofloxacin may prove to be a useful new antichlamydial agent."	( Bailey, JM; Heppleston, C; Richmond, SJ, 1984)
"Levofloxacin is a fluoroquinolone with excellent bioavailability properties that affords potential use in the treatment of a wide variety of infections caused by Gram-positive organisms such as streptococci."	( Biedenbach, DJ; Jones, RN, 1996)
"Ofloxacin is a fluoroquinolone antibiotic that is excreted in the urine as unchanged drug via active tubular secretion and glomerular filtration."	( Cascio, W; Griener, J; Martin, DE; Patterson, JH; Raasch, R; Shen, J, 1996)
"Levofloxacin is a fluoroquinolone antibiotic and is the optical S-(-) isomer of the racemic drug substance ofloxacin. "	( Chow, AT; Fish, DN, 1997)
"Ofloxacin seems to be a good alternative in the treatment of typhoid fever caused by co-trimoxazole resistant salmonellae in children aged less than 16 years."	( Akan, O; Ceyhan, M; Ecevit, Z; Figen, G; Kanra, G; Seçmeer, G, 1997)
"Ciprofloxacin (CPFX) is a widely used fluoroquinolone antibiotic, inducing cutaneous adverse drug reactions in about 1 to 2% of the treated patients. "	( Gleichmann, E; Hunzelmann, N; Rönnau, AC; Ruzicka, T; Sachs, B; Schuppe, HC; von Schmiedeberg, S, 1997)
"Ofloxacin is a broad spectrum fluoroquinolone antibiotic with good ocular penetration. "	( Callina, C; Cohen, RG; Lahav, M; Raizman, M, 1997)
"Ofloxacin is a potent broad-spectrum fluoroquinolone antibiotic commercially available as a topical ophthalmic preparation. "	( , 1997)
"Ofloxacin is a member of 4-Quinolone broad spectrum antibiotics."	( Ceviz, A; Ciçek, R; Gül, K; Inalöz, SS; Sanli, A; Sari, I, 1997)
"Levofloxacin (L-ofloxacin) is a fluoroquinolone derivative. "	( Bornitz, F; Hof, H; Kretschmar, M; Nichterlein, T, 1998)
"Ofloxacin is an established fluoroquinolone agent which achieves good concentrations in genitourinary tract tissues and fluids. "	( Balfour, JA; Lamb, HM; Onrust, SV, 1998)
"Ofloxacin is a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. "	( Markham, A; Simpson, KL, 1999)
"Levofloxacin is a new fluoroquinolone active against S. "	( Léophonte, P; Veyssier, P, 1999)
"Ofloxacin is a broad spectrum fluoroquinolone antibiotic with good ocular penetration. "	( Ahuja, R; Panda, A; Sastry, SS, 1999)
"Levofloxacin is an additional option as monotherapy for the treatment of CAP."	( Idrahim, KY; Lima Nicodemo, E; Nicodemo, AC, 2000)
"Levofloxacin is a useful quinolone for patients infected with osteomyelitis or tuberculosis. "	( Almela, M; Alvárez, JL; García, S; Mensa, J; Ortega, M; Soriano, A; Soriano, E; Tomás, X, 2000)
"Levofloxacin is a valuable addition to the group of fluoroquinolone antibiotics."	( Norrby, SR, 1999)
"Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations."	( Garvin, CG; Jung, R; Martin, SJ, 2001)
"Ofloxacin (OFX) is a fluorquinolone characterized by photochemical instability. "	( Bassani, VL; Eifler-Lima, VL; Guterres, SS; Koester, LS; Le Roch, M; Zuanazzi, JA, 2001)
"Ofloxacin is a fluoroquinolone antibiotic that kills nongrowing cells, and biofilms and stationary-phase cells were comparably tolerant to this antibiotic."	( Lewis, K; Spoering, AL, 2001)
"Ofloxacin is a new broad-spectrum oral bactericidal antimicrobial agent. "	( Diao, Y; Ding, AZ; Xu, DK; Yuan, YS, 1992)
"Ofloxacin proved to be an effective, safe, and comfortable therapy for external bacterial ocular infection."	( Gwon, A, 1992)
"Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. "	( Sanders, WE, 1992)
"Ofloxacin is a new fluoroquinolone with a spectrum of activity similar to other fluoroquinolones with activity which includes Chlamydia trachomatis, Mycobacterium spp., Mycoplasma spp. "	( Bailey, EM; Lamp, KC; Rybak, MJ, 1992)
"Ofloxacin is a new fluoride quinolone which has been shown to be active both in vitro and in vivo against Mycobacterium tuberculosis. "	( Alberte, A; Amón Sesmero, J; Estebanez Zarranz, MJ; Martínez-Sagarra, JM; Rodríguez Toves, A, 1992)
"Ofloxacin is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. "	( Faulds, D; Todd, PA, 1991)
"Ofloxacin is a promising new antibiotic for the treatment of acute lower respiratory infections."	( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991)
"Ofloxacin is a proven antibiotic substance useful in the treatment of lower respiratory tract infections."	( Petermann, W, 1991)
"Ofloxacin was found to be an effective drug with few adverse reactions."	( Boye, NP; Gaustad, P, 1991)
"Ofloxacin is a newly licensed fluoroquinolone with an antimicrobial spectrum similar to ciprofloxacin. "	( Scheld, WM; Tunkel, AR, 1991)
"Ofloxacin is a quinolone carboxylic acid with a broad spectrum of activity for gram-negative pathogens that are common causes of urologic infections including cystitis, pyelonephritis, and prostatitis. "	( Corrado, ML, 1991)
"Ofloxacin is a new fluorinated quinolone antibiotic with a broad spectrum of activity against a variety of gram-positive and -negative bacteria including Enterobacteriaceae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. "	( Rybak, MJ; Smythe, MA, 1989)
"Ofloxacin is a well-tolerated fluoroquinolone antimicrobial agent."	( Smith, JA; Tack, KJ, 1989)
"Ofloxacin was found to be a safe, well-tolerated therapeutic agent, which was as effective clinically as amoxicillin or erythromycin and with an advantage of less frequent administration."	( Garcia, JG; Griffith, DE; Kohler, RB; Stocks, JM; Wallace, RJ, 1989)
"Ofloxacin (Tarivid) is a 4-quinolone of the latest generation. "	( Brugger, P; Klein, G; Kullich, W, 1988)
"Ofloxacin (OFL) is a new broad-spectrum drug with potentially valuable antimycobacterial activity. "	( Crowle, AJ; Elkins, N; May, MH, 1988)
"Ofloxacin is a valuable addition to the range of antimicrobial agents available for the oral treatment of bacterial infection."	( Hancock, P; Harris, K; Leigh, DA; Travers, G; Walsh, B, 1988)
"Ofloxacin appears to be an effective treatment for lower genital tract infections with Ch."	( Nayagam, AT; Oriel, JD; Ridgway, GL, 1988)
"Ofloxacin is a 4-quinolone antibiotic with rapid bactericidal activity against a wide variety of organisms. "	( Drew, RH; Gallis, HA, 1988)
"Ofloxacin is a new fluoroquinolone with excellent in vitro activity against N. "	( Baury, A; Casin, I; Lassau, F; Morel, P; Perol, Y, 1987)
"Ofloxacin is a new fluoroquinolone derivative active against Gram-positive and Gram-negative bacteria including obligate anaerobes. "	( Debbia, E; Gianrossi, G; Mannelli, S; Schito, GC, 1987)
"Ofloxacin is a new oral antibacterial fluoro-quinolone, endowed with potent bactericidal activity over a very broad bacterial spectrum. "	( Caro, B; Erani, E; Guerra, L; Xerri, L, 1987)
"Ofloxacin appears to be an appropriate antibiotic for short term therapy of acute, uncomplicated, lower urinary tract infections, comparing favourably with trimethoprim-sulphamethoxazole treatment in this study."	( Bjertnaes, A; Block, JM; Hafstad, PE; Holte, M; Ottemo, I; Peterson, LE; Rolstad, T; Svarva, PL; Walstad, RA, 1987)
"Ofloxacin proved to be an effective and well-tolerated substance."	( Ludwig, G; Pauthner, H, 1987)
"Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation. "	( Blomer, R; Bruch, K; Zahlten, RN, 1986)
"Ofloxacin is a new fluoroquinolone with in vitro activity against the three main urethritis-causing pathogens: i.e. "	( Bianchi, A; Casin, I; Dolivo, M; Morel, P; Perol, Y, 1986)
"Ofloxacin is a fluoroquinolone that is mainly eliminated through the kidneys. "	( Bryskier, A; Couet, W; Darchis, JP; Fourtillan, JB; Lefebvre, MA; Modai, J; Veyssier, P; Vincent Du Laurier, M, 1986)
"Ofloxacin is a new quinolone carboxylic acid compound. "	( Kumada, T; Neu, HC, 1985)

Excerpt	Reference
"Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections. "	( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004)
"Ofloxacin acyl chloride has a tertiary amino function in its structure and the derivatives from ofloxacin acyl chloride reacting with amino analytes can be ionized by an acid treatment and analyzed by simple capillary zone electrophoresis."	( Chen, SH; Kou, HS; Kwan, AL; Lin, FM; Wu, HL; Wu, SM, 2005)
"Levofloxacin has a tolerability profile similar to that of other oral fluoroquinolones, with gastrointestinal and central nervous system effects reported most commonly."	( Bryson, HM; Davis, R, 1994)
"Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration-time curve (AUC) for an equivalent dose. "	( Holt, HA; MacGowan, AP; Wootton, M, 1999)
"Levofloxacin has a low photosensitizing potential when administered to healthy subjects."	( Boccumini, LE; Campbell, TA; Fowler, CL; Kaidbey, KH; Puertolas, LF, 2000)
"Levofloxacin has a reduced CNS adverse event rate compared with ofloxacin."	( Ball, P, 2000)
"Levofloxacin has a very low phototoxicity-inducing potential confirmed by pre-clinical animal studies and the results of post-marketing surveillance (PMS)."	( Yagawa, K, 2001)
"Ofloxacin has a good safety profile, but, as with other fluoroquinolones, it should not be used in children or in pregnant or nursing women."	( Scheld, WM; Tunkel, AR, 1991)
"Ofloxacin (OX) has been reported as an active antibacterial drug for topical infections and it is effective against both positive and negative bacterial strains."	( Andleeb, A; Azam, M; Khan, A; Mehmood, A; Tehseen, S; Yar, M, 2023)
"Ofloxacin has no significant effect on perinatal outcomes."	( Ahn, HK; Choi, JS; Chung, JH; Han, JY; Ryu, HM; Shin, YJ, 2018)
"Levofloxacin has been proposed to replace clarithromycin for Helicobacter pylori treatment. "	( Graham, DY; Liang, X; Liao, J; Liu, W; Lu, H; Sun, Q; Xiao, S; Zhang, W; Zheng, Q, 2013)
"Ofloxacin (OFX) has been used as second-line drug against MDR-TB."	( Bisht, D; Deo, N; Lata, M; Sharma, D; Tiwari, PK; Venkatesan, K, 2015)
"Levofloxacin, has twice the antimicrobial activity and same toxicity of ofloxacin."	( Kinoshita, H; Koh, M; Morimoto, K, 2002)
"Levofloxacin has good coverage against both Gram-positive and Gram-negative pathogens. "	( Garrison, MW, 2003)
"Levofloxacin has been shown to be effective in Helicobacter pylori eradication. "	( Cammarota, G; Candelli, M; Carloni, E; Cazzato, IA; Cremonini, F; Di Caro, S; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Santarelli, L; Zocco, MA, 2003)
"Ofloxacin has been advocated by the WHO in case of MDR-TB, when susceptibility to test results are not available before starting the new treatment, in the continuation period (18 months) and if resistance is proven to at least isoniazid and rifampicin."	( Gawde, AS; Morye, VK; Walwaikar, PP, 2003)
"Ofloxacin has the best aqueous penetration in human eyes, as compared with ciprofloxacin and tobramycin, which suggests ofloxacin could be the preferred topical medicine for the prevention and treatment of endophthalmitis."	( Wu, XD; Yang, YH; Yao, K; Zhang, Z, 2003)
"levofloxacin has proven to be successful reducing the recurrence rate."	( Sauer, J; Seifert, A; Weyer, T, 2004)
"Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections. "	( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004)
"Levofloxacin has been proposed as an alternative for these refractory infections."	( Branca, G; Cammarota, G; Fadda, G; Gasbarrini, A; Gasbarrini, GB; Schito, AM; Spanu, T, 2004)
"Ofloxacin acyl chloride has a tertiary amino function in its structure and the derivatives from ofloxacin acyl chloride reacting with amino analytes can be ionized by an acid treatment and analyzed by simple capillary zone electrophoresis."	( Chen, SH; Kou, HS; Kwan, AL; Lin, FM; Wu, HL; Wu, SM, 2005)
"Levofloxacin has been proposed as an alternative to classic therapy in secondary resistance to Helicobacter pylori."	( Capodicasa, S; Cappello, G; Coraggio, D; Grossi, L; Marzio, L, 2006)
"Levofloxacin has excellent activity against common respiratory pathogens and therefore is likely to be effective in treating children with persistent or recurrent otitis media."	( Arguedas, A; Blumer, J; Dagan, R; Leibovitz, E; McNeeley, DF; Melkote, R; Noel, GJ; Pichichero, M, 2006)
"Levofloxacin has been evaluated for the treatment of community-acquired pneumonia (CAP) in numerous randomized clinical trials."	( File, TM; Lynch, JP; Zhanel, GG, 2006)
"Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed."	( Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X, 2007)
"Levofloxacin has good tissue penetration and an adequate concentration can be maintained in the urinary tract to treat uropathogens."	( Anderson, VR; Perry, CM, 2008)
"Levofloxacin has a tolerability profile similar to that of other oral fluoroquinolones, with gastrointestinal and central nervous system effects reported most commonly."	( Bryson, HM; Davis, R, 1994)
"Ofloxacin has been reported to diffuse readily into the cerebrospinal fluid (CSF) in subjects with both inflamed and uninflamed meninges. "	( Dreyhaupt, T; Kinzig, M; Kolenda, H; Nau, R; Prange, HW; Sörgel, F, 1994)
"Ofloxacin has potent activity against Gram-negative species but is less effective against Gram-positive species including Streptococcus pneumoniae."	( Bouvet, O; Bressolle, F; Chanez, P; Fabre, D; Galtier, M; Godard, P; Michel, FB; Paganin, F, 1995)
"Ciprofloxacin has the highest activity against Gram-positive is higher than other quinolones."	( Asaoka, T; Imamori, K; Maebashi, K; Matsuda, H; Matsumoto, M; Tahara, Y, 1995)
"Ofloxacin has been used for prevention and treatment of burn infection in 40 burnt subjects. "	( Alekseev, AA; Dutikov, VN; Elagina, LV; Iakovlev, VP; Izotova, GN; Kashin, ID; Krutikov, MG, 1995)
"Ofloxacin has been successfully used in the treatment of typhoid fever and Salmonella infectious of adults for many years. "	( Akan, O; Ceyhan, M; Ecevit, Z; Figen, G; Kanra, G; Seçmeer, G, 1997)
"Ofloxacin has the advantage against ciprofloxacin of exceeding the MICs for Staphylococcus and Chlamydia. "	( Cheng, C; Foo, KT; Li, MK; Png, JC; Rekhraj, IR; Tan, E, 1997)
"Levofloxacin has enhanced activity against pneumococci compared with clinically available quinolones."	( George, J; Morrissey, I, 1997)
"Levofloxacin has demonstrated clinical efficacy in the treatment of community-acquired respiratory-tract infections, genitourinary infections, skin and skin-structure infections, acute bacterial sinusitis, and infections of the head and neck."	( Ernst, EJ; Ernst, ME; Klepser, ME, 1997)
"Ofloxacin has been reported in the literature as a cause of seizures in patients with compromised renal function."	( Hon, JK; Mulpur, TG; Walton, GD, 1997)
"ofloxacin has established efficacy in the treatment of a wide variety of urinary tract infections, although, like other fluoroquinolones, it should be used rationally to preserve its activity. "	( Balfour, JA; Lamb, HM; Onrust, SV, 1998)
"Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration-time curve (AUC) for an equivalent dose. "	( Holt, HA; MacGowan, AP; Wootton, M, 1999)
"Ofloxacin has been formulated as a 0.3% otic solution for the treatment of ear infections."	( Markham, A; Simpson, KL, 1999)
"Levofloxacin has been reported to have in vitro activity against both gram-positive and gram-negative bacteria. "	( Amicosante, G; Franceschini, N; Marchetti, F; Perilli, M; Segatore, B; Setacci, D, 2000)
"Levofloxacin has a low photosensitizing potential when administered to healthy subjects."	( Boccumini, LE; Campbell, TA; Fowler, CL; Kaidbey, KH; Puertolas, LF, 2000)
"Levofloxacin has such an activity profile."	( Boccumini, L; Corrado, M; Drusano, GL; Gombert, M; Kahn, J; North, D; Oefelein, M; Preston, SL; Van Guilder, M; Weisinger, B, 2000)
"Ofloxacin has superior antibacterial effect under the conditions studied."	( Goldberg, MA; Lustbader, J; MacDowell, AL; Melki, SA; Safar, A; Scharper, M; Scharper, P; Yaghouti, F; Zeligs, B, 2000)
"Ofloxacin has not been associated with ototoxicity in animal models or in children participating in the clinical trials."	( Goldblatt, EL, 2001)
"Levofloxacin has been involved in only a few case reports of adverse events, which include QTc prolongation, seizures, glucose disturbances, and tendonitis."	( Garvin, CG; Jung, R; Martin, SJ, 2001)
"Levofloxacin has a reduced CNS adverse event rate compared with ofloxacin."	( Ball, P, 2000)
"Levofloxacin has a very low phototoxicity-inducing potential confirmed by pre-clinical animal studies and the results of post-marketing surveillance (PMS)."	( Yagawa, K, 2001)
"Ofloxacin has antitubercular activity and has exclusive renal clearance."	( Agarwal, SR; Nandeesh, HP; Saigal, S; Sarin, SK, 2001)
"Ciprofloxacin has better activity against gram-negative bacilli, an advantage which may be negated by ofloxacin's longer half-life and higher serum levels."	( Nicolau, D; Nightingale, CH; Quintiliani, R, 1992)
"Ofloxacin has favorable pharmacokinetics with almost 100% bioavailability; peak serum concentrations obtained one to two hours following oral dosing are higher than those achieved with ciprofloxacin."	( Scheld, WM; Tunkel, AR, 1991)
"Ofloxacin has certain attributes that make it a potentially useful drug in the treatment of urologic infections."	( Corrado, ML, 1991)
"Ofloxacin has been evaluated in an in vitro model where microorganisms were exposed to the varying concentrations met in human serum after the oral administration of a 200 mg dose. "	( Broggio, R; Guerra, L; Xerri, L, 1986)
"Ofloxacin has proven to be effective in soft tissue infections and pneumonia after surgical intervention."	( Fritzen, T; Marx, E; Uy, J, 1986)

Excerpt	Reference
"Levofloxacin can cause severe thrombocytopenia. "	( Polprasert, C; Prayongratana, K, 2009)
"Levofloxacin may produce a faster clinical response than older macrolides, allowing for shorter hospital stay."	( Carratalà, J; Dorca, J; Fernández-Sabé, N; Gudiol, F; Manresa, F; Mykietiuk, A; Verdaguer, R, 2005)
"Ciprofloxacin and ofloxacin inhibit proliferation and DNA synthesis of these 3 human TCC lines in vitro. "	( Dixon, PS; Peretsman, SJ; Seay, TM, 1996)
"Ofloxacin can cause retarded ossification and arthropathy in young animals, but there is no published information about its teratogenicity in humans. "	( Friedman, S; Hod, M; Merlob, P; Peled, Y, 1991)
"Ofloxacin generated lower titers, ranging from 1:14 for indole-positive Proteus spp."	( Machka, K; Milatovic, D, 1987)
"Ofloxacin did not cause any point mutations, nor did it induce any in vivo or in vitro chromosome mutation in the systems tested."	( Bruch, K; Mayer, D, 1986)

Excerpt	Reference
"Ofloxacin treatment failed to counter the bacterial proliferation in Pyn-STm coinfected mice."	( Maurya, AK; Mittal, S; Pal, A; Pandey, AK; Patel, DK; Singh, D; Tiwari, N, 2018)
"Levofloxacin treatment did not affect the cytokine mRNA level and nuclear factor-κB-dependent promoter activity."	( Dudley, MN; Griffith, DC; Lomovskaya, O; Sabet, M; Tarazi, Z; Tsivkovskii, R, 2011)
"Levofloxacin treatment was stopped and the patient made a full recovery."	( Figueira-Coelho, J; Mendonça, P; Neta, J; Neves-Costa, J; Pereira, O; Picado, B, 2010)
"Levofloxacin treatment abolished bacteremia within 24 h in animals with confirmed pre-infusion bacteremia, and reduced tachypnea and leukocytosis but not fever during the first 2 days of infusions."	( Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W, 2011)
"Levofloxacin-based treatment for H. "	( Aresti-Zárate, S; Ayestarán, B; Campos, MR; Carrascosa, MF; Cobo, M; Cuadrado-Lavín, A; Dierssen-Sotos, T; Fernández-Pousa, A; González-Colominas, E; Hernández, M; Pascual, EL; Salcines-Caviedes, JR, 2012)
"Ofloxacin-treated patients showed increased endotoxin neutralizing capacity (ENC) 30 min after clamping compared to controls (15.8+/-15 vs 262.8+/-709 p=0.005) and increased IL-6 levels preoperatively and 30 min after clamping."	( Holzheimer, RG, 2003)
"Ciprofloxacin/dexamethasone treatment is also superior to improvement in clinical response by visit, absence of otorrhea by visit, and reduction of otorrhea volume by visit."	( Anon, JB; Conroy, PJ; Dupre, SJ; Hogg, G; Kreisler, LS; Lanier, B; McLean, C; Potts, S; Reese, B; Roland, PS; Stroman, DW; Wall, GM, 2004)
"Levofloxacin treatment at 24 hours, but not at 0 hours, resulted in a significant decrease in the number of C."	( Baltch, AL; Bopp, LH; Carlyn, CJ; Carpenter, AN; Hibbs, JR; Michelsen, PB; Ritz, WJ; Smith, RP, 2004)
"Levofloxacin treatment was supplemented with piperacillin/tazobactam."	( Bettaccini, AA; Brigante, G; Endimiani, A; Grossi, P; Luzzaro, F; Toniolo, AQ, 2005)
"Levofloxacin treatment had no effect on IL-6 activities and concentrations in uninfected broilers."	( Cheng, GF; Gu, CQ; Hu, XY; Li, XM; Wang, DH; Zhou, Q; Zhou, SQ, 2007)
"Both ofloxacin-placebo treatment and tobramycin-erythromycin treatment were more effective than no treatment in sterilizing the external ocular adnexa. "	( Discepola, MJ; Goldstein, DA; Jackson, WB; Kirsch, LS, 1995)
"Levofloxacin-treated mice (40 mg/kg once a day) showed no evidence of pyelonephritis in the kidneys, whereas the kidneys of mice treated with the same dose of ciprofloxacin showed only a reduction in the severity of the lesions."	( Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996)
"Ofloxacin treatment gave good result in reduction of otorrhea, regardless of the earlier treatment of chronic otitis media."	( Dzelalija, B; Kovacić, M, 1999)
"Ofloxacin treatment led to significantly more biofilm eradication than the other antibiotic group on day 4 (62 vs."	( Delaney, G; Hayes, K; Hsieh, J; Nicosia, S; Potter, P; Reid, G, 2000)
"Levofloxacin treatment failed in a patient who had pneumococcal pneumonia and had received three previous courses of levofloxacin therapy."	( Denys, GA; Kays, MB; Smith, DW; Wack, ME, 2002)
"Ofloxacin treatment did not change the total magnesium concentrations in tissues, as determined with ashed samples."	( Lozo, E; Riecke, K; Schwabe, R; Stahlmann, R; Vormann, J, 2002)
"Ofloxacin treatment eradicated or controlled 85% (86/101) of the Gram positive and 89% (17/19) of the Gram negative organisms cultured, compared with 83% (103/124) and 78% (29/37), respectively, after gentamicin treatment."	( Gwon, A, 1992)
"Ofloxacin treatment was discontinued in three patients."	( Ammälä, K; Aro, A; Backman, R; Keistinen, T; Lehtipuu, AL; Punakivi, L; Saarelainen, P; Veneskoski, T; Vilkka, V, 1990)
"Ofloxacin treatment was used for the treatment of lower respiratory tract infections in 35 patients."	( Regamey, C; Steinbach-Lebbin, C, 1990)
"Ofloxacin by pretreatment with five oral doses of 50 mg/kg did not increase serum concentrations of theophylline (5 mg/kg, i.v."	( Miyazaki, K; Okazaki, O; Tachizawa, H, 1987)
"A treatment with ofloxacin for 7 days was inferior to 14 days for febrile UTI in men and should therefore not be recommended."	( Abgrall, S; Aparicio, C; Aumaitre, H; Bercot, B; Bernard, L; Bourgarit-Durand, A; Bruyere, F; Canoui, E; Chabrol, A; Charlier, C; Chevret, S; de Lastours, V; Desseaux, K; Empana-Barat, F; Escaut, L; Etienne, M; Ferreyra, M; Fontaine, JP; Garrait, V; Gatey, C; Grall, N; Jaureguiberry, S; Lafaurie, M; Lefort, A; Madeleine, I; Meyssonnier, V; Molina, JM; Mongiat-Artus, P; Morrier, M; Pacanowski, J; Piet, E; Talarmin, JP, 2023)
"Treatment with ofloxacin resulted in a bacteriological conversion similar to that following conventional treatment ( p>0.05, Fisher's exact test)."	( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002)
"The treatment with ofloxacin in accordance with the above scheme resulted in a rapid improvement of the patient state: the intoxication lowered, the expectoration and the sputum viscosity decreased, the body temperature normalized by the 5th day."	( Apul'tsina, ID; Chuchalin, AG; GUgutsidze, EN; Kuchkina, NV; Samsonova, MV; Sokolov, AS, 1996)
"Treatment with ofloxacin in a combined regimen achieved a success rate of 78%."	( Maranetra, KN, 1999)
"Treatment with ofloxacin significantly reduced the need for additional courses of antibiotics (28.4%, 12.9-43.9, p=0.0006)."	( Abroug, F; Belghith, M; Besbes, L; Elatrous, S; Marghli, S; Nouira, S, 2001)
"Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls."	( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991)
"Pretreatment with ofloxacin and norfloxacin did not influence theophylline disposition, but theophylline clearance fell from 0.054 to 0.027 l.h-1.kg-1 in the presence of enoxacin, without a change in the apparent volume of distribution."	( Goto, M; Kawakatsu, K; Ohkita, C; Sano, M; Takeyama, M; Yamamoto, I; Yamashina, H, 1988)
"Treatment with ofloxacin in 15 patients with chronic renal failure at different stages is reported with respect to patients undergoing hemodialysis treatment. "	( Dörfler, A; Schulz, W, 1986)

Class	Description
3-oxo monocarboxylic acid
N-methylpiperazine
N-arylpiperazine
oxazinoquinoline	Any organic heterotricyclic compound based on a skeleton comprised of an oxazine ring fused onto a quinoline system.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	112.2020	0.0032	45.4673	12,589.2998	AID2517
Chain A, HADH2 protein	Homo sapiens (human)	Potency	17.5595	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	17.5595	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	17.3955	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	31.6228	5.6234	17.2929	31.6228	AID2323
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	29.7506	0.1000	20.8793	79.4328	AID488772; AID588453; AID588456
TDP1 protein	Homo sapiens (human)	Potency	19.7611	0.0008	11.3822	44.6684	AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.5648	0.0112	12.4002	100.0000	AID1030
EWS/FLI fusion protein	Homo sapiens (human)	Potency	20.9310	0.0013	10.1577	42.8575	AID1259252; AID1259253
arylsulfatase A	Homo sapiens (human)	Potency	4.2562	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	32.5733	0.0355	20.9770	89.1251	AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	14.1406	0.0018	15.6638	39.8107	AID894
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	32.6427	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	79.4328	3.5481	19.5427	44.6684	AID743266
flap endonuclease 1	Homo sapiens (human)	Potency	37.6858	0.1337	25.4129	89.1251	AID588795
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	19.9526	0.2512	15.8432	39.8107	AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	566.5000	0.1100	7.1903	10.0000	AID1449628; AID1473738
DNA gyrase subunit A	Escherichia coli K-12	IC50 (µMol)	1.5000	0.0239	0.5629	5.2300	AID530379
DNA gyrase subunit B	Escherichia coli K-12	IC50 (µMol)	1.5000	0.0050	0.4398	5.2300	AID530379
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5057	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.4973	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.4988	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5046	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5065	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5057	10.0000	AID71980; AID71981
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
DNA gyrase subunit B	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	28.0000	0.0150	2.4676	10.0000	AID530368
DNA gyrase subunit A	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	28.0000	0.0150	3.4773	10.0000	AID530368
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	1,414.0320	0.0009	1.9014	10.0000	AID161281; AID243151; AID408340; AID576612; AID755684
GABA theta subunit	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	IC50 (µMol)	55.5000	0.0001	0.5075	10.0000	AID71980; AID71981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
streptokinase A precursor	Streptococcus pyogenes M1 GAS	EC50 (µMol)	3.6940	0.0600	8.9128	130.5170	AID1902
Albumin	Homo sapiens (human)	Kd	12.0000	0.0893	3.3135	8.0000	AID557095
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
STE24	Saccharomyces cerevisiae (brewer's yeast)	AC50	1.9500	1.9500	6.6870	11.8600	AID488815
CAAX prenyl protease	Saccharomyces cerevisiae S288C	AC50	100.0000	1.0790	17.9906	68.9400	AID488788
Trypsin	Sus scrofa (pig)	AC50	9.2640	3.3400	16.7050	77.2200	AID488789
DNA gyrase subunit A	Escherichia coli K-12	CC25	0.2000	0.2000	0.3500	0.5000	AID530391
DNA gyrase subunit B	Escherichia coli K-12	CC25	0.2000	0.2000	0.3500	0.5000	AID530391
DNA gyrase subunit B	Mycobacterium tuberculosis H37Rv	CC25	7.0000	2.0000	4.5000	7.0000	AID530380
DNA gyrase subunit A	Mycobacterium tuberculosis H37Rv	CC25	7.0000	2.0000	4.5000	7.0000	AID530380
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
DNA topological change	DNA gyrase subunit A	Escherichia coli K-12
DNA-templated transcription	DNA gyrase subunit A	Escherichia coli K-12
response to xenobiotic stimulus	DNA gyrase subunit A	Escherichia coli K-12
DNA-templated DNA replication	DNA gyrase subunit A	Escherichia coli K-12
DNA topological change	DNA gyrase subunit A	Escherichia coli K-12
response to antibiotic	DNA gyrase subunit A	Escherichia coli K-12
chromosome organization	DNA gyrase subunit A	Escherichia coli K-12
negative regulation of DNA-templated DNA replication	DNA gyrase subunit A	Escherichia coli K-12
DNA topological change	DNA gyrase subunit B	Escherichia coli K-12
DNA-templated transcription	DNA gyrase subunit B	Escherichia coli K-12
response to xenobiotic stimulus	DNA gyrase subunit B	Escherichia coli K-12
DNA-templated DNA replication	DNA gyrase subunit B	Escherichia coli K-12
DNA topological change	DNA gyrase subunit B	Escherichia coli K-12
response to antibiotic	DNA gyrase subunit B	Escherichia coli K-12
chromosome organization	DNA gyrase subunit B	Escherichia coli K-12
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
DNA binding	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase activity	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA gyrase subunit A	Escherichia coli K-12
protein binding	DNA gyrase subunit A	Escherichia coli K-12
ATP binding	DNA gyrase subunit A	Escherichia coli K-12
ATP-dependent activity, acting on DNA	DNA gyrase subunit A	Escherichia coli K-12
DNA negative supercoiling activity	DNA gyrase subunit A	Escherichia coli K-12
identical protein binding	DNA gyrase subunit A	Escherichia coli K-12
DNA binding	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase activity	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA gyrase subunit B	Escherichia coli K-12
protein binding	DNA gyrase subunit B	Escherichia coli K-12
ATP binding	DNA gyrase subunit B	Escherichia coli K-12
ATP-dependent activity, acting on DNA	DNA gyrase subunit B	Escherichia coli K-12
DNA negative supercoiling activity	DNA gyrase subunit B	Escherichia coli K-12
metal ion binding	DNA gyrase subunit B	Escherichia coli K-12
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
chromosome	DNA gyrase subunit A	Escherichia coli K-12
cytoplasm	DNA gyrase subunit A	Escherichia coli K-12
cytosol	DNA gyrase subunit A	Escherichia coli K-12
membrane	DNA gyrase subunit A	Escherichia coli K-12
cytoplasm	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA gyrase subunit A	Escherichia coli K-12
chromosome	DNA gyrase subunit B	Escherichia coli K-12
cytoplasm	DNA gyrase subunit B	Escherichia coli K-12
cytosol	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA gyrase subunit B	Escherichia coli K-12
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1631)

Assay ID	Title	Year	Journal	Article
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID447218	Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562930	Antimicrobial activity against Clostridium difficile CD07-259 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID209087	Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-2	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID127505	In vitro antibacterial activity against glucose nonfermenter Moraxella bovis P-7101	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID391988	Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1163980	Antimycobacterial activity against isoniazid, rifampicin, ofloxacin and kanamycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 clinical isolate after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
AID1230207	Antibacterial activity against Bacillus cereus N258 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID530388	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID562782	Antimicrobial activity against Chlamydia trachomatis L2/oflR harboring ompA gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID70428	Compound was tested for antibacterial activity against gram negative Escherichia coli ML4707	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID510156	Antimicrobial activity against Staphylococcus aureus ATCC 35218 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID1368746	Antibacterial activity against Escherichia coli MTCC 443 at 1 ug/ml under overnight incubation condition by paper disc method	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Synthesis and biological evaluation of 1-amino isochromans from 2-bromoethyl benzaldehyde and amines in acid medium.
AID200881	Tested in vitro against Salmonella Typhimurium IID971 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID563502	Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID371460	Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID64885	Tested for inhibitory activity against DNA gyrase supercoiling in Escherichia coli (KL-16)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID524824	Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1230227	Antibacterial activity against Enterococcus gallinarum N489 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID572525	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2017 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID531337	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID371464	Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID1193922	Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID428985	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 104 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID733008	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID128018	Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID395361	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID532981	Antibacterial activity against Escherichia coli DH5alpha	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1331878	Antibacterial activity against Salmonella enterica ATCC 14028	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID206437	In vitro antibacterial activity against clinical isolates of Staphylococcus aureus 18773 (gram-positive) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID1695812	Antibacterial activity against Escherichia coli assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID1324013	Permeability of the compound at 100 ug/ml after 16 hrs by PAMPA-BBB method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID293582	Antibacterial activity against Klebsiella pneumoniae isolate assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID1274482	Antibacterial activity against Escherichia coli JM 109 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID287371	Antibacterial activity against Escherichia coli after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID203039	Minimum inhibitory concentration required in vitro against Shigella	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID207258	Tested in vitro for antibacterial activity against Staphylococcus aureus (FDA 209P JC-1)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1743440	Antibacterial activity against Mycobacterium smegmatis measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID520423	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU18 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID1516026	Antibacterial activity against Acinetobacter baumannii AB1901 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID572516	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2944 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID530424	Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID164395	Antimicrobial activity against the Pseudomonas aeruginosa K 799/61 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID322314	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID1224525	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID498787	Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID352091	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID530384	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID540227	Volume of distribution at steady state in monkey after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID163228	Compound was tested for antibacterial activity against gram negative Proteus vulgaris No.33	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID1662846	Antibacterial activity against Staphylococcus aureus ATCC 209p	2020	Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13	Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action.
AID1823665	Apparent permeability across basolateral to apical side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Discovery of New Imidazo[2,1-
AID316447	Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID530383	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID70860	Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 2646	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID429013	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT60 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID562927	Antimicrobial activity against Clostridium difficile ATCC 43603-M1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID164709	Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-18	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1653574	Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.375 ug/ml in presence of 0.05 ug/ml rifabutin measured at 4 weeks	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID562797	Antimicrobial activity against Chlamydia trachomatis L2/tetR1 harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1577333	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 9449/2007 after 21 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID572511	Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate s2878 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID562928	Antimicrobial activity against Clostridium difficile ATCC 43603 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID550048	Antibacterial activity against Escherichia coli assessed as inhibition of visible growth after 48 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds.
AID1167608	Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis XDR-TB after 28 days by two-fold agar dilution method	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
AID563228	Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1274479	Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID1331879	Antimycobacterial activity against Mycobacterium smegmatis MC2 155	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID581497	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D500N mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID530409	Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1230214	Antibacterial activity against Enterococcus durans CIP 104999 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1485937	Permeability of the compound in PBS/EtOH after 16 hrs by PAMPA-BBB assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1570739	Antimicrobial activity against Listeria monocytogenes clinical isolate at 5 ug/disk incubated for 20 +/- 4 hrs by agar disk diffusion method	2019	Bioorganic & medicinal chemistry, 11-01, Volume: 27, Issue:21	Synthesis and evaluation of 1,3,4-oxadiazole derivatives for development as broad-spectrum antibiotics.
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1907629	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC2858 incubated for 18 to 20 hrs by double dilution method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1331872	Antibacterial activity against vancomycin-resistant Enterococcus	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID144565	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID530245	Antimicrobial activity against apaH deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli.
AID352095	Antimicrobial activity against ceftriazone-resistant Bacillus subtilis after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID679031	TP_TRANSPORTER: inhibition of DNP-SG uptakee (DNP-SG: 1 uM, OFLX: 10000 uM) in bile canalicular membrane vesicles from SD rat	1998	The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3	Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID203167	Tested in vitro against Serratia marcescens IAM1184 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID520871	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU57 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID9222	Activity against Acinetobacter calcoaceticus (AC54)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID1377751	Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID371462	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID1743467	Inhibition of DNA gyrase in Escherichia coli ATCC 25922 assessed as elongation of bacterial cells at 2 ug/ml measured after 1.5 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID694231	Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition by BACTEC method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.
AID1138550	In vivo antibacterial activity against Staphylococcus aureus in New zealand rabbit keratitis model assessed as suppression of conjuctival congestion, conjuctival chemosis, infiltration, operative ulcer area and depth at 3 mg/ml administered topically ever	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.
AID1653556	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.0062 ug/ml KRM-1648 measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID385166	Antimicrobial activity against Enterococcus faecalis by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID532988	Antibacterial activity against Klebsiella aerogenes NCIM 2281	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID532987	Antibacterial activity against Pseudomonas aeruginosa NCIM 5029 in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1412154	Bactericidal activity against methicillin-resistant Staphylococcus aureus 15 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID322316	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID95540	Tested in vitro for antibacterial activity against Klebsiella pneumoniae (B54)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID535837	Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID562783	Antimicrobial activity against Chlamydia suis S45/rifR harboring rpoB gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1435653	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 7357/1998 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID69782	Antibacterial activity against Escherichia coli (H560)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID429017	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG7 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID424879	Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID429022	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG152 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID67531	Inhibition of growth of Entero. cloacae	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID557096	Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID209225	In vitro antibacterial activity against Streptococcus faecalis 2473	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID1516028	Antibacterial activity against Pseudomonas aeruginosa 25349 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID206368	Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus faecalis MGH-2	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID581502	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94A mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID542140	Antimicrobial activity against Salmonella enterica HN-GSS2007-0.033 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID1378880	Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID542146	Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrS1 gene by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID1557280	Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID559366	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID581500	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB A90V and T539P mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID203037	Minimum bactericidal concentration required in vitro against Shigella	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID209061	In vitro antibacterial activity against Streptococcus epidermis 8	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID581510	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and D500A mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1557279	Antibacterial activity against Escherichia coli by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID656233	Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID1557287	Antibacterial activity against Enterococcus by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID563225	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1653573	Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.75 ug/ml in presence of 0.2 ug/ml rifampin measured at 4 weeks	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID133980	In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered subcutaneously	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID395365	Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID205965	Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus UC-76	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID352837	Antimicrobial activity against Aspergillus fumigatus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID70947	In vitro antibacterial activity against clinical isolates of Escherichia coli 15 (gram negative) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID1412149	Antibacterial activity against Staphylococcus epidermidis ATCC 35984 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID1502712	Antimycobacterial activity against Mycobacterium avium isolate MAV3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID574808	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID562241	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID279820	Antimicrobial activity against Mycobacterium tuberculosis H3Rv on day 7	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID563031	Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1301203	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis harbouring Beijing genotype with combination of mutations of Ser 53-Leu 315 and Ser-Thr in rpoB and katG genes after 10 days by micro broth dilution method	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.
AID1230244	Antibacterial activity against Staphylococcus haemolyticus CIP 8156 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID530619	Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1188153	Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID1743471	Inhibition of DNA gyrase in Mycobacterium smegmatis assessed as segmentation of bacterial cells at 2 ug/ml measured after 6 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID530410	Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID207385	Inhibition of growth of Staphylococcus aureus (sensitive)	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID67215	Compound was tested for antibacterial activity against gram positive Enterococcus faecalis 1373	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID559579	Antimicrobial activity against Parachlamydia acanthamoebae infected in Acanthamoeba castellanii amoeba cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID396101	Antibacterial activity against Pseudomonas aeruginosa OCR1 overexpressing mexAB by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID530413	Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1463957	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 4 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID530422	Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559561	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID162775	In vitro minimum inhibitory concentration against Pseudomonas aeruginosa (ATCC 27853)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID316451	Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse spleen assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID530617	Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID529671	Antimicrobial activity against azide-resistant Escherichia coli J53 by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID530426	Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID206283	In vitro antibacterial activity against Staphylococcus aureus 209P JC-1	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID562939	Effect on fbp69 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID43924	Compound was tested for antibacterial activity against gram negative Burkholderia cepacia 23	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID562784	Antimicrobial activity against Chlamydia trachomatis J/6276/rifR harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID562245	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562788	Antimicrobial activity against Chlamydia muridarum MoPn/rifRoflR harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID523002	Cytotoxicity against human 5637 cells assessed as mild induction of cell death by LDH release assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID349880	Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID563055	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1309353	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 24 hrs by microbroth dilution method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.
AID534424	Antibacterial activity against Mycobacterium bovis BCG-Pasteur	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
AID557093	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID557094	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID521968	Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID563043	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID524825	Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID563032	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1743462	Antitubercular activity against Mycobacterium tuberculosis XDR measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID68846	In vitro minimum inhibitory concentration against Escherichia coli KC-14	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID406846	Antibacterial activity against Escherichia coli TOP10 containing pS1A plasmid expressing quinolone resistance determinant QnrB4 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1171213	Antibacterial activity against tolC-deficient Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID151536	Tested in vitro against Pseudomonas aeruginosa IFO3445 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1152758	Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 27294 after 16 to 18 days by BACTEC 7H12B microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1672289	Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID1823666	Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Discovery of New Imidazo[2,1-
AID563040	Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1695811	Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID131700	Effective dose against Escherichia coli KC14 strain in mouse	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID1230225	Antibacterial activity against Enterococcus faecium N823 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID70926	In vitro antibacterial activity against Escherichia coli P-5101	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID535838	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID530403	Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID161281	Inhibition of human Potassium channel HERG expressed in mammalian cells	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID562242	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID295112	Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID574589	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID406845	Antibacterial activity against Escherichia coli TOP10 containing pS1B plasmid expressing quinolone resistance determinant QnrS1 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID498188	Antibacterial activity against Stenotrophomonas maltophilia MBS108 containing both chromosomally and plasmid encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID572513	Antimicrobial activity against Salmonella enterica serovar Mbandaka isolate s2159 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID293583	Antibacterial activity against Pseudomonas aeruginosa isolate assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID1421886	Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1562257	Antimycobacterial activity against Mycobacterium smegmatis atR2 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID1435650	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID206643	Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID408340	Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Support vector machines classification of hERG liabilities based on atom types.
AID1174112	Antimycobacterial activity against isoniazid, rifampin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID1478786	Permeability of the compound at 200 uL after 16 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
AID391987	Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1743457	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID433403	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID563048	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID164385	Antibacterial activity against Pseudomonas aeruginosa (UI-18)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1347980	Permeability of the compound in PBS/EtOH at 100 ug/ml after 12 hrs by PAMPA-BBB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID530615	Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1264447	Permeability of the compound by PAMPA method	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID293590	Antibacterial activity against Bacillus subtilis ATCC 6633 assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID1230212	Antibacterial activity against Enterococcus casseliflavus N487 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID405120	Antimicrobial activity against Escherichia coli TOP10 harbouring p0 plasmid expressing pCR-BluntII-TOPO	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID1152777	Antimycobacterial activity against 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID117675	Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (sc)	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID563017	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID433400	Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID498190	Antibacterial activity against Stenotrophomonas maltophilia MBS82 deficient in Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID205546	Minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 13709	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Antibacterial activity of quinolone-macrocycle conjugates.
AID1730991	Antitubercular activity against drug susceptible Mycobacterium tuberculosis V4207 by MABA assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID563046	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563219	Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID425069	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID316445	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID1653575	Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.375 ug/ml in presence of 0.0125 ug/ml KRM-1648 measured at 4 weeks	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID542147	Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrD gene by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID1230243	Antibacterial activity against Staphylococcus epidermidis CIP 53124 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID396097	Antibacterial activity against Staphylococcus aureus K1758-P by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID765109	Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition at 2 ug/mL relative to control	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.
AID530616	Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1113447	Antibacterial activity against Proteus vulgaris assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1174108	Antimycobacterial activity against isoniazid, rifampin, ethambutol, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID532038	Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfPS012 harboring PMQR determinant qnrB22 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID581509	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1653552	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.75 ug/ml in presence of 0.1 ug/ml rifampin measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID563503	Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID532982	Antibacterial activity against Escherichia coli W3110 in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID52937	Compound was tested for antibacterial activity against gram negative Citrobacter freundii KP-29	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID94051	Tested in vitro against Klebsiella pneumoniae PCI-602 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID295121	Antibacterial activity against Micrococcus luteus La 2971 at 5 ug by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID425072	Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID563027	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID450458	Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID559358	Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID562829	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID696005	Permeability of the compound after 4 hrs by PAMPA assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
AID162914	In vitro antibacterial activity against clinical isolates of Proteus morganii 27 (gram negative) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID530405	Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID352089	Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID406844	Antibacterial activity against Escherichia coli TOP10 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID559552	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1823664	Apparent permeability across apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	Discovery of New Imidazo[2,1-
AID1113448	Antibacterial activity against Escherichia coli assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID122923	Minimum inhibitory concentration against gram-positive MI, Micrococcus luteus ATCC 9341.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID520873	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU69 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID450460	Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1167550	Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1743461	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly/gyrB Asp-500-Asn mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1349194	Antichlamydial activity against Chlamydia trachomatis serovar L2 infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis.
AID1502710	Antimycobacterial activity against Mycobacterium avium isolate MAV1 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID763998	Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 15 mm)	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID562798	Antimicrobial activity against Chlamydia muridarum MoPn/tetR14 harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID428998	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1516020	Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID542148	Antimicrobial activity against Escherichia coli DH10B harboring p2007057 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID164712	Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa E-2 (Pa(E))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID532035	Antimicrobial activity against azide-resistant Escherichia coli J53 TrcPS012 harboring PMQR determinant qnrB22 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID559364	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1705959	Effective permeability of compound at 100 ug/ml incubated for 20 hrs by PAMPA-BBB assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID78715	Inhibition constant against DNA Gyrase isolated from Micrococcus luteus	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID1360040	Antimicrobial activity against Escherichia coli after 18 to 20 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID206890	Antibacterial activity against Staphylococcus aureus UC76	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID532033	Antimicrobial activity against Citrobacter werkmanii PS012 expressing PMQR determinant qnrB22 gene by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID428990	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 45 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID498781	Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID164703	Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa PAO1	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID1662849	Bactericidal activity against Bacillus cereus	2020	Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13	Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action.
AID562931	Antimicrobial activity against Clostridium difficile 6269 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID205651	Compound was tested for antibacterial activity against gram positive Staphylococcus aureus JS-1	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID41268	In vitro minimum inhibitory concentration against Bacteroides fragilis (ATCC 25285)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID395360	Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID530406	Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1055941	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID656231	Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID164702	Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa KP-254	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID535833	Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID542141	Antimicrobial activity against Salmonella enterica HN-GSS2007-0.056 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID279821	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 1	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID559578	Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Vero cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID559367	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID209279	Antimicrobial activity against the streptococcus pyogenes EES 61 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID572147	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID324747	Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1171217	Antibacterial activity against wild-type Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743458	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Gly-88-Cys mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1412156	Bactericidal activity against methicillin-resistant Staphylococcus epidermidis 57 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID206174	Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID1907643	Antibiofilm activity against methicillin-resistant Staphylococcus aureus ATCC2858 assessed as minimal biofilm eradication concentration incubated for 24 hrs by crystal violet staining based assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.
AID143122	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 90%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID1463956	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 1 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID70735	Evaluated for minimum inhibitory concentration against gram-negative bacteria Escherichia coli Vogel	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID428994	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 32 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID133813	Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID563050	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID198343	Tested in vitro against Staphylococcus aureus FDA209P JC-1 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID352833	Antimicrobial activity against Rhodotorula rubra NCIM 3174 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID208131	In vitro minimum inhibitory concentration against Streptococcus pneumoniae (ATCC 6301)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID1557295	Cmax in human at 0.4 g, po bid	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID205596	In vitro minimum inhibitory concentration against gram-positive Se, Staphylococcus epidermidis IAM 1296.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID665368	Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate at 10 ug/mL by radiometric growth assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antimycobacterial activity of novel 1,3-dimethylisocyanurate derivatives.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID498782	Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID563012	Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID423635	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs	2009	Journal of natural products, Apr, Volume: 72, Issue:4	Terpenoids from Toona ciliata.
AID1331871	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID1173784	Inhibition of Mycobacterium tuberculosis DNA gyrase using relaxed pBR322 as substrate after 30 mins by supercoiling assay	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID581504	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94N mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID63896	Activity against Enterobacter aerogenes (ATCC 13048)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID428993	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 51 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID316449	Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse lungs assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID151670	Minimum inhibition concentration against Pseudomonas aeruginosa U-31 strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID733007	Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID163048	Inhibition of growth of Proteus rettgeri	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID563338	Induction of Cwp84 protease expression in Clostridium difficile CD196 M1 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1662848	Antibacterial activity against Bacillus cereus	2020	Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13	Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action.
AID563337	Induction of Cwp84 protease expression in Clostridium difficile CD196 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID78688	Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID581506	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA G88A mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID510170	Antimicrobial activity against Enterococcus faecalis ATCC 29212 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1171215	Antibacterial activity against wild-type Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID427197	Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID352621	Antimicrobial activity against Salmonella Typhimurium NCIM 2501 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1274481	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1437026	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by agar dilution method	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
AID559359	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID151530	Tested in vivo against Pseudomonas aeruginosa E-2 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1224521	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID530408	Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559564	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1193921	Inhibition of Mycobacterium smegmatis DNA GyrB domain assessed as inhibition of inorganic phosphate release after 100 mins at room temperature by ATPase assay	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID352629	Antimicrobial activity against Pseudomonas aeruginosa NCIM 2200 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1557286	Antibacterial activity against Streptococcus pyogenes by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1173786	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID133979	In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered perorally	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID428900	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID131401	Oral efficacy against Streptococcus pyogenes A65 on Systemic Infections in Mice	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID1511118	Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID581494	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94G mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID287379	Antibacterial activity against Pseudomonas aeruginosa after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID28899	Calculated partition coefficient (clogP)	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID117674	Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (po)	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID574790	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID209067	Antibacterial activity against Streptococcus faecalis MGH-2	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID1331876	Antibacterial activity against Klebsiella pneumoniae ATCC 27736	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1055939	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 20 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID71794	Percentage of GABA-induced chloride currents with 10e-4 M 4-biphenylacetic acid	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID209462	In vitro antibacterial activity against Streptococcus pyogenes A65	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID164704	In vitro minimum inhibitory concentration against gram-negative Pa(E), Pseudomonas aeruginosa E-2.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID429023	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG168 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID562945	Upregulation of cwp84 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID165055	In vitro antibacterial activity against clinical isolates of Pseudomonas aeruginosa 2437 (gram negative) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID40925	Tested in vitro against Bacillus subtilis ATCC 6633 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID70564	Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(K), Escherichia coli KC-14.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID563224	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID293589	Antibacterial activity against Escherichia coli ATCC 25922 assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID574809	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID209730	Inhibition of growth of Streptococcus pneumonia	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID1557284	Antibacterial activity against Staphylococcus aureus by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1188156	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID572523	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2052 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1352674	Effective permeability at 25 ug/ml after 16 hrs by PAMPA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1174110	Antimycobacterial activity against isoniazid, rifampin, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID563332	Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1295091	Tuberculostatic activity against multi-drug resistant Mycobacterium tuberculosis isolates assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1309354	Antimycobacterial activity against Mycobacterium avium after 24 hrs by microbroth dilution method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.
AID285684	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with pvdS mutation after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID562800	Antimicrobial activity against Chlamydia trachomatis F/70/rifR-tetR harboring rpoB gene and tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1743442	Antibacterial activity against Mycobacterium marinum measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID530379	Inhibition of Escherichia coli DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559361	Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID530402	Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID429033	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT76 harboring wild type DNA gyrase A by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1230223	Antibacterial activity against Enterococcus faecium N507 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID428995	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 33 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1193920	Inhibition of Mycobacterium tuberculosis DNA GyrA/B heterotetramer assessed as inhibition of pBR322 supercoiling after 30 mins by gel electrophoresis	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID530421	Antimicrobial activity against Helicobacter pylori harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID534344	Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID71980	Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID1188155	Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID532985	Antibacterial activity against Escherichia coli MG1655	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID563018	Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID559362	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID530378	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID531336	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID530411	Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID293588	Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID429034	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1163982	Cytotoxicity against mouse RAW264.7 cells at 50 uM after 72 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
AID656227	Antimycobacterial activity against isoniazid-, rifampin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID535836	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID450459	Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID164396	Antimicrobial activity against the Pseudomonas aeruginosa K 799/WT by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID447216	Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID559576	Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Acanthamoeba castellanii amoeba cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID433404	Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID687497	Clearance in rat	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID542145	Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrA1 gene by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID733004	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB G89C mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID1730995	Antitubercular activity against extensively drug resistance Mycobacterium tuberculosis R506 XDR by MABA	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
AID510157	Antimicrobial activity against cephalosporin-resistant Acinetobacter baumannii by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID285682	Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID405121	Antimicrobial activity against Escherichia coli TOP10	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID562244	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1279155	Permeability of the compound at 25 ug/ml at pH 7.4 after 18 hrs by PAMPA	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID295100	Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID534337	Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1907630	Antibacterial activity against Escherichia coli incubated for 18 to 20 hrs by double dilution method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.
AID69619	Antibacterial activity against Escherichia coli H560	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID94363	In vitro antibacterial activity against Klebsiella pneumoniae K-1966	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID530394	Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID208737	Minimum inhibitory concentration required in vitro against Streptococcus D	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID322313	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID295097	Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID498191	Antibacterial activity against Stenotrophomonas maltophilia MBS101 containing plasmid encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID70571	Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID532980	Antibacterial activity against Escherichia coli DH5alpha in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID71795	Percentage of GABA-induced chloride currents with compound alone at 10 e-4 M	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID529159	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID105366	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID429006	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT37 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID205665	In vitro minimum inhibitory concentration against gram-positive Sa (I), Staphylococcus aureus IID803.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID563215	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID53311	Inhibitory effect on DNA gyrase supercoiling activity from Escherichia coli K-12 C600	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID428987	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate nar 108 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID563015	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID520875	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolates isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID205924	Antimicrobial activity against the faecium ATCC 8043 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID1907628	Antibacterial activity against Staphylococcus aureus ATCC6538 incubated for 18 to 20 hrs by double dilution method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.
AID429026	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG182 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID559365	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1174107	Antimycobacterial activity against isoniazid, rifampin, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID665367	Antitubercular activity against Mycobacterium tuberculosis H37Rv at 10 ug/mL by radiometric growth assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antimycobacterial activity of novel 1,3-dimethylisocyanurate derivatives.
AID687499	Drug excretion in rat urine	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID285683	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with rpoN mutation after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID395778	Antibacterial activity against ceftriaxone-resistant Bacillus subtilis isolate after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID1557281	Antibacterial activity against Klebsiella by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID391979	Antibacterial activity against Enterococcus faecalis JH2-2-delta-pG1KT mutant by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID563051	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID293584	Antibacterial activity against Escherichia coli isolate assessed after 24 hrs by by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID1730992	Antitubercular activity against multi drug resistance Mycobacterium tuberculosis V2475 by MABA assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
AID395364	Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID498189	Antibacterial activity against Stenotrophomonas maltophilia MBS109 containing chromosomally encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID428984	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 102 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID207175	Antibacterial activity against Staphylococcus aureus (H228)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID559557	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1743441	Antibacterial activity against Mycobacterium aurum measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1412157	Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID287377	Antibacterial activity against Mycobacterium smegmatis after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID164706	In vitro minimum inhibitory concentration against gram-negative Pa(I), Pseudomonas aeruginosa IFO 3445.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID529456	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID391981	Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT/pORI23::qnr-cat mutant with qnr gene complementation by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID65384	Minimum inhibition concentration against Enterococcus faecalis LS-101 strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID392220	Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID560590	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID535841	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID352805	Antimicrobial activity against Bacillus cereus NCIM 2155 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID563212	Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID637605	Permeability of the compound by PAMPA	2012	European journal of medicinal chemistry, Feb, Volume: 48	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
AID563023	Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene and deletion of codons 678 and 679 in gyrB mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID96075	Antimicrobial activity against the klebsiella pneumoniae 8045 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530417	Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559558	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID762022	Antibacterial activity against Pseudomonas aeruginosa 9027 measured every 24 hrs for 5 days by conventional dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID559581	Antimicrobial activity against Chlamydophila pneumoniae infected in Vero cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID563339	Induction of Cwp84 protease expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID535840	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1230215	Antibacterial activity against Enterococcus faecalis CIP 103214 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID534418	Antibacterial activity against Mycobacterium bovis BCG-Russia	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
AID550047	Antibacterial activity against Staphylococcus aureus assessed as inhibition of visible growth after 48 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds.
AID563026	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1230247	Antibacterial activity against Staphylococcus saprophyticus CIP 76125 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1694879	Permeability of compound after 16 hrs by PAMPA-BBB assay	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID562792	Antimicrobial activity against Chlamydophila caviae GPIC/rifR harboring rpoB gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID559555	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID96228	Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Kp, Klebsiella pneumoniae B54.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID1557283	Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID206854	Minimum bactericidal concentration required in vitro against Staphylococcus aureus	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID529160	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID396104	Antibacterial activity against Escherichia coli AG100 by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID1152781	Ratio of MIC for 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant to MIC for wild-type Mycobacterium tuber	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1230220	Antibacterial activity against Enterococcus faecium CIP 103014 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1360043	Bactericidal activity against Bacillus cereus after 24 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID1909448	Permeability of the compound by PAMPA-BBB assay	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1516027	Antibacterial activity against Acinetobacter baumannii AB1902 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1230226	Antibacterial activity against Enterococcus gallinarum CIP 105985 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1743444	Antibacterial activity against Pseudomonas aeruginosa measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID295109	Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID395363	Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID1743456	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1377752	Effective permeability of the compound at 25 ug/ml by PAMPA assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID1516086	Resistance index, ratio of MIC for antibacterial activity against ciprofloxacin-resistant Escherichia coli to MIC for Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID53321	Inhibition of DNA gyrase supercoiling in Escherichia coli.	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	DNA gyrase inhibitory activity of ellagic acid derivatives.
AID67545	Activity against Enterobacter aerogenes	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID530372	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID352092	Antimicrobial activity against multidrug-resistant Escherichia coli after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID1463958	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 131 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID529670	Antimicrobial activity against Escherichia coli J53 transconjugate by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID1274477	Antibacterial activity against Methicillin-resistant Staphylococcus aureus N 315 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID429003	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT9 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID133954	In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered subcutaneously	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID510168	Antimicrobial activity against extended spectrum beta lactamase expressing Klebsiella pneumoniae by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID1295090	Tuberculostatic activity against Mycobacterium terrae assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1230213	Antibacterial activity against Enterococcus casseliflavus CIP 103018 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID532037	Antimicrobial activity against azide-resistant Escherichia coli J53 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID203276	Antimicrobial activity against the Staphylococcus aureus 45 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID563039	Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1577331	Antimycobacterial activity against XDR Mycobacterium tuberculosis Praha 131 after 14 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID540231	Dose normalised AUC in dog after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID557099	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at >145 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID429012	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT54 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1173785	Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID428979	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate E86 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID532034	Antimicrobial activity against Citrobacter freundii S008 expressing PMQR determinant qnrB23 gene by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID450461	Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1662847	Bactericidal activity against Staphylococcus aureus ATCC 209p	2020	Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13	Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action.
AID542142	Antimicrobial activity against Salmonella enterica HN-GSS-2007-057 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID1224527	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1412158	Bactericidal activity against Pseudomonas aeruginosa isolate 1 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID1516019	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1230221	Antibacterial activity against Enterococcus faecium CIP 107387 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID562932	Antimicrobial activity against Clostridium difficile 6425 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID429016	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG6 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID530385	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID95885	Antibacterial activity against Klebsiella pneumonia (MGH-2)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID163554	Tested in vitro against Proteus vulgaris OX-19 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID559360	Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID395717	Antibacterial activity against Escherichia coli DH10B containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID162777	In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IFO 3445	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID206284	In vitro antibacterial activity against Staphylococcus aureus 50774	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1309358	Acute toxicity in po dosed mouse	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.
AID135327	BBB penetration classification	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID562240	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID198342	Tested in vivo against Staphylococcus aureus IID803 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1230241	Antibacterial activity against Staphylococcus aureus CIP 7625 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID293587	Antibacterial activity against Klebsiella pneumoniae RSHM 574 assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID162740	Compound was tested for antibacterial activity against gram negative Proteus mirabilis JY-10	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID429028	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG259 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID96098	Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae KC-1	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID574796	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID733009	Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration causing =<1% reduction in bacterial growth incubated for 21 to 30 days by proportion method	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID1335284	Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of DNA supercoiling activity using relaxed pBR322 as substrate incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1557285	Antibacterial activity against Streptococcus pneumoniae by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1480942	Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID530392	Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID324745	Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID521967	Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1349196	Antichlamydial activity against Chlamydia trachomatis serovar A 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis.
AID540225	Volume of distribution at steady state in dog after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID206812	Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pyogenes C203	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID69626	Antibacterial activity against Escherichia coli Vogel	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID205652	Compound was tested for antibacterial activity against gram positive Staphylococcus aureus KP-90-3	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID1463962	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 8666/2010 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID530623	Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID510167	Antimicrobial activity against Klebsiella pneumoniae RSKK 574 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID1730994	Antitubercular activity against isoniazid/rifampin/levofloxacin/ofloxacin/kanamycin extensively drug resistance Mycobacterium tuberculosis TF274 XDR by MABA assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
AID271563	Residual activity of human CK2 at 30 uM	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
AID694360	Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition by BACTEC method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID563341	Induction of Cwp84 protease expression in Clostridium difficile 6269 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID207260	Tested in vitro for antibacterial activity against Staphylococcus aureus (IID 803)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID395775	Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID563340	Effect on Cwp84 protease expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID562785	Antimicrobial activity against Chlamydia muridarum MoPn/oflR harboring ompA gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID534341	Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID429027	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG258 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID198344	Tested in vitro against Staphylococcus aureus IID803 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID131003	Compound was tested for oral efficacy on systemic infections caused by Staphylococcus aureus IID803 in mice	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID1593376	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in extensively drug-resistant Mycobacterium tuberculosis TF274 assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID540226	Clearance in monkey after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID532036	Antimicrobial activity against azide-resistant Escherichia coli J53 TrcS008 harboring PMQR determinant qnrB23 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID144017	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID283088	Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA at 5 ug by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID352841	Antimicrobial activity against Aspergillus parasiticus NCIM 904 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID572151	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID521966	Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID534346	Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID450457	Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1177575	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by microdilution method	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus.
AID562943	Upregulation of slpA gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID200334	Minimum bactericidal concentration required in vitro against Salmonella	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID1143269	Antimycobacterial activity against ethambutol-resistant Mycobacterium tuberculosis 17003 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID1295088	Tuberculostatic activity against Mycobacterium tuberculosis H37Rv assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1762620	Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as reduction in bacterial growth after 6 to 8 days by green fluorescent protein microplate assay
AID163732	Antibacterial activity against Providencia rettgeri M1771	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID1511119	Permeability of the compound at 25 ug/ml by PAMPA-BBB assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID131400	Oral efficacy against Pseudomonas aeruginosa 12 on Systemic Infections in Mice	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID122920	Antimicrobial activity against the micrococcus luteus 9341 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID1623120	Effective permeability of the compound by BBB-PAMPA method	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID574583	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID530618	Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID65203	Minimum inhibitory concentration against Escherichia coli KC14 strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID694359	Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.
AID1174106	Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID540233	Dose normalised AUC in human after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID67219	Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Enterococcus faecalis IID682 (Ef)	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID733005	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB A91V mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID95891	Inhibition of growth of Klebsiella pneumonia	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID1360037	Antimicrobial activity against Staphylococcus aureus after 18 to 20 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID1230238	Antibacterial activity against Staphylococcus aureus CIP 53154 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1773264	Permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1296388	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 131 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID405115	Antimicrobial activity against Vibrio splendidus LGP32 expressing plasmid-mediated QnrS-like quinolone resistance determinants	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID563330	Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1653555	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.05 ug/ml rifabutin measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID352096	Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID207390	In vitro antibacterial activity against Staphylococcus aureus 209P JC-1	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1404015	Permeability of the compound after 2.5 hrs by PAMPA	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID205805	Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus IID 803 (Sa(I))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID572519	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2425 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID520870	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU47 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID70429	Compound was tested for antibacterial activity against gram negative Escherichia coli NIHJ JC-2	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID681306	TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 0.03 uM, Ofloxacin: 21.7 mg/mL) in HL60R cells: flow cytometric analysis	2000	Antimicrobial agents and chemotherapy, Jun, Volume: 44, Issue:6	Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.
AID1595267	Antibacterial activity against Escherichia coli assessed as inhibition zone incubated for 24 hrs by disk diffusion method relative to control	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.
AID563024	Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID297186	Antibacterial activity against multidrug resistant Staphylococcus aureus 49589	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.
AID755684	Inhibition of human ERG current by patch clamp assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1503776	Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells after 70 hrs by fluorescent microscopic analysis	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID562787	Antimicrobial activity against Chlamydia suis R19/tetR harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID163738	Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H1771	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID433580	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID442658	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives.
AID69479	Minimum inhibitory concentration against Escherichia coli ATCC 25922	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Antibacterial activity of quinolone-macrocycle conjugates.
AID200869	In vitro minimum inhibitory concentration against Salmonella Typhimurium IID 971	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1174109	Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID765104	Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.
AID205964	Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus H228	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID530419	Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID133812	Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1301204	Cytotoxicity against human FEH cells after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.
AID534338	Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID209894	Antibacterial activity against Streptococcus pneumoniae SV-1	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID1143266	Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis 136570 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID1174111	Antimycobacterial activity against isoniazid, rifampin, ethambutol-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID1435648	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID429010	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT48 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID542139	Antimicrobial activity against Salmonella enterica HN-GSS2006-142 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID17991	Bioavailability	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID1743448	Antibacterial activity against Staphylococcus aureus measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID206632	Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 50% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range)	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID574784	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID563041	Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID530620	Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID562940	Effect on fbp69 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1279139	Permeability of the compound at 25 ug/ml at pH 7.4 after 16 hrs by PAMPA	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID530390	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID656232	Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID293585	Antibacterial activity against Bacillus subtilis isolate assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID530414	Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID352845	Antimicrobial activity against Penicillium chrysogenum NCIM 707 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID498192	Antibacterial activity against Stenotrophomonas maltophilia MBS100 deficient in Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID1695809	Antibacterial activity against Bacillus subtilis assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID763999	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 16 mm)	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID559556	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1129167	Permeability of the compound by PAMPA	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
AID287375	Antibacterial activity against Micrococcus luteus after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID581505	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94Y mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID529161	FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID429004	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT15 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID206825	Compound was tested for antibacterial activity against gram positive Staphylococcus pyogenes cook	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID285687	Increase in GFP tagged vqsR protein expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml by flow cytometry relative to wild type	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID202106	Minimum inhibition concentration against Streptococcus pneumoniae Type I strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID1201746	Permeability of the compound after 16 hrs by PAMPA	2015	European journal of medicinal chemistry, May-05, Volume: 95	Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID1113446	Antibacterial activity against Salmonella enterica subsp. enterica serovar Typhi assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID429030	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate BL 21801 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID530423	Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID279818	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774A.1 macrophages	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID557091	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID433581	Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A G89C mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1230210	Antibacterial activity against Corynebacterium striatum N840 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID78707	MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID428901	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1264455	Permeability of the compound by high throughput PAMPA method	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID563209	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563029	Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID572150	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID405118	Antimicrobial activity against Escherichia coli TOP10 harbouring pS1 plasmid expressing quinolone resistant QnrS1 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID395772	Antibacterial activity against Klebsiella pneumoniae isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID1730993	Antitubercular activity against isoniazid/rifampin resistance Mycobacterium tuberculosis KZN494 by MABA assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
AID563334	Upregulation of slpA gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID691688	Antibacterial activity against Bartonella henselae infected in african green monkey Vero cells by immunofluorescence staining	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	Studies on the antimicrobial properties of N-acylated ciprofloxacins.
AID524826	Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1331869	Antibacterial activity against Bacillus subtilis 168	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID203190	In vitro antibacterial activity against Shigella flexneri 2a EW-10	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID449435	Antimycobacterial activity against Mycobacterium tuberculosis XDR infected in MDBK by BACTEC analysis	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID352825	Antimicrobial activity against Aspergillus niger NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID74727	Antibacterial activity against five Gram-negative bacteria	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID1743449	Antibacterial activity against Klebsiella pneumoniae measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID530391	Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID574802	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID765112	Bacteriostatic activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.
AID1152776	Antimycobacterial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA A74V mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID763997	Antibacterial activity against Shigella flexneri ATCC 15391 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 17 mm)	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID524827	Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID562828	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID535842	Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID133807	Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID530369	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID581503	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID67217	In vitro minimum inhibitory concentration against gram-positive Ef Enterococcus faecalis IID 682.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID1230219	Antibacterial activity against Enterococcus faecalis N520 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID429024	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG169 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID498187	Antibacterial activity against Stenotrophomonas maltophilia D457 containing chromosomally encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID510169	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID563218	Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1557282	Antibacterial activity against Bacteroides fragilis by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1390097	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 50 ug/ml after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis.
AID1315652	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv measured daily for 8 days by GFP-based fluorescence assay	2016	Journal of natural products, 06-24, Volume: 79, Issue:6	Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178.
AID535834	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID428982	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT29 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID295853	Antimicrobial activity against Streptococcus pyogenes KUKEM676 by disk diffusion method at 10 ug/disc	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID395780	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID206370	In vitro minimum inhibitory concentration against Streptococcus faecalis (ATCC 29212)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID694367	Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.
AID96099	Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae No.42	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID687496	Half life in rat	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID428978	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate B111 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID562794	Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR1 harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1502706	Antimycobacterial activity against Mycobacterium avium 104 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID687493	Oral bioavailability in rat	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID96230	Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Klebsiella pneumoniae B54 (Kp)	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID530427	Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID534421	Antibacterial activity against Mycobacterium bovis BCG-Denmark	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
AID70427	Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RK1	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID207201	In vitro minimum inhibitory concentration against Staphylococcus aureus (ATCC 29213)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID163786	Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (IFO 3445)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1231418	Antibacterial activity against Bacillus cereus ATCC 14579 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of caracasine acid derivatives.
AID295115	Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID396099	Antibacterial activity against Staphylococcus aureus K1902 by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID1593377	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in extensively drug-resistant Mycobacterium tuberculosis R506 assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID447215	Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID572520	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Virginia isolate s2219 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1231420	Antibacterial activity against Escherichia coli ATCC 35218 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of caracasine acid derivatives.
AID206877	Antibacterial activity against Staphylococcus aureus H-228	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID433402	Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID530407	Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID396103	Antibacterial activity against Escherichia coli AG102 overexpressing acrAB by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1577327	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 1 after 14 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID70781	In vitro antibacterial activity against Escherichia coli NIH JC-2	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1672290	Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID1412153	Bactericidal activity against Staphylococcus aureus ATCC 6538 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID322318	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID352821	Antimicrobial activity against Proteus vulgaris NCIM 2027 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID535845	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID352801	Antimicrobial activity against Bacillus subtilis NCIM 2063 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1319973	Permeability of the compound by PAMPA assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID429005	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID207207	In vitro minimum inhibitory concentration against Staphylococcus aureus IID 803	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID563010	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID560259	Antimicrobial activity against Salmonella enterica serovar Typhimurium STYM61/9 expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID540229	Volume of distribution at steady state in human after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID681771	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, OFLX: 2000 uM) in Xenopus laevis oocytes	1999	The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2	The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID1230224	Antibacterial activity against Enterococcus faecium N733 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1562256	Antimycobacterial activity against Mycobacterium smegmatis atR40 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID560592	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID563331	Upregulation of slpA gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1413649	Ratio of MIC for methicillin-resistant Staphylococcus aureus JCSC 4788 re-passaged at 24 hrs intervals for 20 times to MIC for methicillin-resistant Staphylococcus aureus JCSC 4788	2018	MedChemComm, Oct-01, Volume: 9, Issue:10	Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.
AID67549	Antimicrobial activity against the enterobacter aerogenes ATCC 13048 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID510161	Antimicrobial activity against Proteus mirabilis ATCC 7002 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID532990	Antibacterial activity against Klebsiella pneumoniae NCIM 2883 assessed as growth inhibition in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID279841	Drug level in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID64252	Activity against Escherichia coli (K-12 C600)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID1478796	Permeability of the compound by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
AID164873	Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas aeruginosa UI-18	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID1324014	Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID535846	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID279817	Antimicrobial activity against Mycobacterium tuberculosis H37Rv in 7H9 broth	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID207206	In vitro minimum inhibitory concentration against Staphylococcus aureus FDA 209P JC-1	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID65221	Minimum inhibition concentration against Escherichia coli NIHJ JC-2 strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID1390094	Antimycobacterial activity against active form of Mycobacterium tuberculosis H37Rv measured after 7 days by alamar blue assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis.
AID687494	Cmax in rat at 10 mg/kg, iv	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID428986	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 107 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1516024	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID68976	Minimum concentration of the drug needed to produce linear DNA at an intensity relative to oxolinic acid(at 10 ug/mL)	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID530387	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID534339	Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1056992	Permeability of the compound by PAMPA	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1273398	Anti-tubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294T after 7 days by mircodilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID285686	Increase in vqsR gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml relative to wild type	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID133817	Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1335283	Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in BL21(DE3)pLysS cells assessed as inhibition of DNA supercoiling activity in presence of ATP measured after 30 mins by malachite green dye based assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID70570	Compound was tested for inhibition of the gram-negative organism Escherichia coli H560	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID405117	Antimicrobial activity against Escherichia coli TOP10 harbouring pVS2 expressing quinolone resistant Vibrio splendidus LGP32 QnrVS2 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID71070	Concentration required to produce linear DNA from closed circular DNA by the denaturation of the drug-gyrase-DNA complex	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID68013	Antibacterial activity against Enterobacter cloacae MA2646	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID572522	Antimicrobial activity against qnrA-positive Salmonella enterica serovar Mbandaka isolate s2093 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID94137	Activity against Klebsiella pneumoniae (PCI-602)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID563208	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID531332	Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID391985	Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL by agarose gel electrophoresis	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID203278	Antimicrobial activity against the Staphylococcus epidermis 3519 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID581513	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94G mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID530244	Antimicrobial activity against Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli.
AID69951	Antimicrobial activity against the Escherichia coli H560 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID534343	Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID563045	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID206197	Tested in vitro for antibacterial activity against Staphylococcus epidermidis (IAM 1296)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID535844	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID68849	In vitro minimum inhibitory concentration against Escherichia coli (ATCC 1-25922)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID530377	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1557288	Antibacterial activity against Clostridium perfringens by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID279839	Ratio of fraction AUC in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID530412	Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID531334	Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID1412155	Bactericidal activity against Staphylococcus epidermidis ATCC 35984 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID563030	Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID447080	Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID1163979	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
AID563216	Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID447219	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID1113451	Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1421885	Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID114660	Compound was evaluated for oral Pseudomonas aeruginosa E-2	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID371463	Antimicrobial activity against Escherichia coli isolate after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID532039	Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfS008 harboring PMQR determinant qnrB23 by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID1516029	Antibacterial activity against Staphylococcus aureus 11011 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID520872	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU67 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID572517	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Braenderup isolate s2856 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID559363	Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID208946	Inhibition of growth of Streptococcus pyogenes	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID563009	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID78692	50% inhibitory concentration against DNA-gyrase	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID1516023	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID562944	Upregulation of fbp68 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID429007	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT40 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1230216	Antibacterial activity against Enterococcus faecalis CIP 104676 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID64889	Tested in vitro for antibacterial activity agains Escherichia coli (NIHJ JC-2)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1412150	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 57 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID395715	Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID563016	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID208740	Antimicrobial activity against the streptococcus agalactiae CMX 508 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID428991	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 46 harboring DNA gyrase A D87G mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID563333	Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID424862	Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID1295089	Tuberculostatic activity against Mycobacterium avium assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID151057	Activity against Pseudomonas aeruginosa (E-2)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID563336	Induction of Cwp84 protease expression in Clostridium difficile 6425 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID427198	Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID352094	Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID198023	Activity against Streptococcus faecalis (IID 682)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1480849	Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
AID70770	Inhibition of growth of Escherichia coli H560	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID429036	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID201406	Minimum inhibitory concentration against Staphylococcus aureus Smith	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID68172	Compound was tested for antibacterial activity against gram negative Enterobacter cloacae Nek39	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID429001	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT2 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1577329	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 4 after 14 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID562926	Antimicrobial activity against Clostridium difficile CD196 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1301202	Antimycobacterial activity against Mycobacterium terrae after 10 days by micro broth dilution method	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.
AID371461	Antimicrobial activity against Bacillus subtilis isolate after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID1463961	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 7357/1998 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID563056	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID429002	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT3 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1171223	Ratio of MIC for wild-type Escherichia coli to MIC for tolC-deficient Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID559563	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID542144	Antimicrobial activity against Escherichia coli DH10B harboring pBR322 by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID540230	Dose normalised AUC in rat after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID563042	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID498872	Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID1224523	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID656230	Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID557092	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID562933	Upregulation of slpA gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID532986	Antibacterial activity against Pseudomonas aeruginosa NCIM 5029	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID391984	Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL in presence of 0.9 uM histidine6-tagged Enterococcus faecalis qnr protein preincubated before compound administration by agarose gel electrophoresis	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID395774	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID433401	Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID535835	Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID279830	Half life in BALB/c mouse at 37.5 to 2400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID352097	Antimicrobial activity against multidrug-resistant Staphylococcus aureus after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID562937	Upregulation of cwp84 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID68848	In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID96249	In vitro antibacterial activity against Klebsiella pneumoniae 13	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID510159	Antimicrobial activity against extended spectrum beta lactamase expressing Proteus mirabilis by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID530376	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1562258	Antimycobacterial activity against Mycobacterium smegmatis atR19 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID433578	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID95916	Antibacterial activity against Klebsiella pneumoniae MGH-2	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID285685	Increase in pvdS gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml after 3 hrs relative to wild type	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID540224	Clearance in dog after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID562942	Upregulation of cwp84 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1143264	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID560261	Antimicrobial activity against Escherichia coli CSH26RifR receiving qnrB19 gene variant carried by IncL/M-like plasmid from Salmonella enterica serovar Typhimurium STYM61/9 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID1743447	Antibacterial activity against Enterobacter cloacae measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID279819	Fraction unbound ligand in mouse plasma at 0.01 to 50 mg/litre	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID424863	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID209302	Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1230246	Antibacterial activity against Staphylococcus lugdunensis ATCC 43809 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID395359	Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID510163	Antimicrobial activity against Pseudomonas aeruginosa ATCC 10145 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID540223	Volume of distribution at steady state in rat after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID529457	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID114659	Compound was evaluated for oral efficacy on systemic infections in mice by Escherichia coli KC-14	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1230236	Antibacterial activity against Staphylococcus aureus ATCC 9144 oxford after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID562793	Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR2 harboring ampA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID534345	Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID28851	The compound was evaluated for the solubility in water at 25 degrees Centigrade	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID352817	Antimicrobial activity against Staphylococcus albus NCIM 2178 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID560591	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID395776	Antibacterial activity against Escherichia coli isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID659472	Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
AID206794	Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID293591	Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID405119	Antimicrobial activity against Escherichia coli TOP10 harbouring pS2 plasmid expressing quinolone resistant QnrS2 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID200345	Minimum inhibitory concentration required in vitro against Salmonella	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID279823	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 14	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID559368	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID540222	Clearance in rat after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562786	Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR1 harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1230235	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID534342	Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID164268	Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas rettgeri H1771	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID352090	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID96229	Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-2	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID530398	Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID110152	Percentage of mice with convulsion (400 mg/kg fenbufen)	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID687498	Volume of distribution in rat	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID208735	Minimum bactericidal concentration required in vitro against Streptococcus D	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID562929	Antimicrobial activity against Clostridium difficile CD196 M1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1743469	Inhibition of DNA gyrase in Mycobacterium smegmatis assessed as elongation of bacterial cells at 2 ug/ml measured after 6 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1331873	Antibacterial activity against Acinetobacter baumannii ATCC 19606	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID1435654	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID1274478	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID198018	Activity against Staphylococcus epidermidis (IAM 1296)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID635079	Permeability of the compound after 2.5 hrs by PAMPA-BBB assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
AID532983	Antibacterial activity against Escherichia coli W3110	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID562934	Upregulation of slpA gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID207384	Inhibition of growth of Staphylococcus aureus (resistant)	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID205389	Compound was tested for antibacterial activity against gram negative Serratia marcescens No.16-2	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID694227	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.
AID530371	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID563036	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID64884	Tested in vitro for antibacterial activity against Escherichia coli (KC-14)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID164701	Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa K-13	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID385168	Antimicrobial activity against Staphylococcus aureus by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID1485936	Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID279837	Reduction of Mycobacterium tuberculosis H37Rv in orally dosed BALB/c mouse lung	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID385164	Antimicrobial activity against Candida albicans by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID1743460	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val/gyrB Glu-540-Val mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID563038	Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID581499	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying mutation	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1230245	Antibacterial activity against Staphylococcus intermedius N987 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1435652	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID425073	Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID1113450	Antibacterial activity against Klebsiella pneumoniae assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1693561	Effective permeability of compound in PBS/EtOH buffer (7:3) at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
AID1143270	Antimycobacterial activity against ofloxacin-resistant Mycobacterium tuberculosis 12119 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID687495	AUC (0 to infinity) in rat at 10 mg/kg, iv	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.
AID1703921	Permeability of the compound by PAMPA-BBB assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1437020	Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis clinical isolate after 4 days by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives.
AID1230217	Antibacterial activity against Enterococcus faecalis N491 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID95735	Compound was tested for antibacterial activity against gram negative Klebsiella oxytoca GN 10650	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID510164	Antimicrobial activity against extended spectrum beta lactamase expressing Escherichia coli by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1230229	Antibacterial activity against Enterococcus hirae CIP 5855 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID563058	Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID559371	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID205806	Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus FDA 209P JC-1 (Sa(F))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID574806	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID143107	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID532984	Antibacterial activity against Escherichia coli MG1655 in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID530370	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID395366	Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID131701	Effective dose against Staphylococcus aureus smith strain in mouse	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID1577339	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1623078	Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1653557	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.0125 ug/ml KRM-1648 measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID352853	Antimicrobial activity against Trichoderma viride NCIM 1195 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1230228	Antibacterial activity against Enterococcus gallinarum N492 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID762020	Antibacterial activity against Bacillus cereus 8035 measured every 24 hrs for 5 days by conventional dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID243151	Inhibitory concentration against potassium channel HERG	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID540232	Dose normalised AUC in monkey after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1171218	Antibacterial activity against MeXABCDXY-deficient Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID762019	Antibacterial activity against Escherichia coli F-50 measured every 24 hrs for 5 days by conventional dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID1143267	Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 912253 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID1230250	Antibacterial activity against Streptococcus agalactiae CIP 103227 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID562935	Upregulation of slpA gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID510158	Antimicrobial activity against Acinetobacter baumannii RSKK 02026 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID469403	Permeability across PAMPA membrane	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID520869	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU33 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID532040	Antimicrobial activity against azide-resistant Escherichia coli DH5alpha by Etest	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.
AID205881	In vitro minimum inhibitory concentration against Staphylococcus epidermidis IAM 1296	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID352809	Antimicrobial activity against Vibrio fischeri NCIM 2154 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1143265	Antimycobacterial activity against Mycobacterium tuberculosis D-211 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID563049	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID395718	Antibacterial activity against Escherichia coli DH10B containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID163961	In vitro antibacterial activity against Pseudomonas aeruginosa E-2	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID563217	Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1412148	Antibacterial activity against methicillin-resistant Staphylococcus aureus 15 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID143859	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID1171224	Ratio of MIC for wild-type Pseudomonas aeruginosa to MIC for MeXABCDXY-deficient Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID542143	Antimicrobial activity against Escherichia coli DH10B by broth microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin.
AID1335286	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM measured after 72 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID581511	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and T539P mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID562243	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID572512	Antimicrobial activity against Salmonella enterica serovar Montevideo isolate s2317 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID210196	Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-1	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID395781	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID581493	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94A mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID96264	In vitro antibacterial activity against clinical isolates of Klebsiella pneumoniae-4 (gram negative) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID406847	Antibacterial activity against Enterobacter cloacae S1 isolate expressing quinolone resistance determinant QnrB4 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID396100	Antibacterial activity against Pseudomonas aeruginosa K1536 overexpressing mexCD by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID523001	Cytotoxicity against human 5637 cells assessed as mild induction of cell death by trypan blue exclusion assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID1230249	Antibacterial activity against Staphylococcus sciuri N993 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID68201	In vitro antibacterial activity against clinical isolates of Enterobacter cloacae 041 (gram negative) by agar dilution assay.	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.
AID70575	Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli KC-14 (Ec(K))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID1593375	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in multidrug-resistant Mycobacterium tuberculosis KZN494 assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID559580	Antimicrobial activity against Chlamydia trachomatis infected in Vero cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID557098	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 18 to 36 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1126743	Antibacterial activity against 0.5 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID386887	Antimicrobial activity against Candida albicans ATCC 2091 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID563052	Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID574810	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1593373	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in drug-susceptible Mycobacterium tuberculosis V4207 assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID71981	Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID352813	Antimicrobial activity against Corynebacterium rubrum NCIM 2252 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID429035	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID51918	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID530386	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID572510	Antimicrobial activity against Salmonella enterica serovar Braenderup isolate s2906 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID133810	Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1055943	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID70576	Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli NIHJ JC-2 (Ec(N))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID1301201	Antimycobacterial activity against Mycobacterium avium after 10 days by micro broth dilution method	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.
AID562824	Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID498780	Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID530380	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559550	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID559554	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1230208	Antibacterial activity against Bacillus cereus N349 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID563059	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1347981	Permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID144567	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 90%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID206034	Tested in vitro against Staphylococcus epidermidis IAM12896 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID572514	Antimicrobial activity against Salmonella enterica serovar Corvallis isolate s2064 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1230218	Antibacterial activity against Enterococcus faecalis N518 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1890598	Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID203277	Antimicrobial activity against the Staphylococcus aureus ATCC 6538 P by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID560601	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID144019	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 90%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID385165	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID581507	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D500N mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID324749	Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 150 mg/kg/day after 9 months	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID563222	Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1866897	Permeability for across blood brain barrier by PAMPA	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
AID1331874	Antibacterial activity against Enterobacter cloacae ATCC 13047	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID1360039	Antimicrobial activity against Pseudomonas aeruginosa after 18 to 20 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID563500	Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID563033	Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID405114	Antimicrobial activity against Vibrio splendidus 12B01 expressing plasmid-mediated QnrS-like quinolone resistance determinants	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID279840	Ratio of fraction Cmax in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID574807	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID429011	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT49 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID763993	Antibacterial activity against Shigella flexneri ATCC 15391 after 24 hrs by two-fold serial dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID530396	Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID563221	Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563035	Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID209126	Antibacterial activity against Streptococcus pyogenes C203	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID1502709	Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID295103	Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID530622	Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1672292	Antifungal activity against Candida albicans assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID287376	Antibacterial activity against Proteus vulgaris after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID352829	Antimicrobial activity against Aspergillus flavus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID428988	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate ipt 2 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID205663	Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-positive Sa (F) Staphylococcus aureus FDA 209P JC-1	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID208910	Antimicrobial activity against the streptococcus bovis A 5169 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID429025	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG176 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID429021	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG17 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1173783	Inhibition of purified Mycobacterium smegmatis GyrB at 50 to 100 uM after 100 mins by ATPase assay	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID563211	Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene assessed as microbial susceptibility and deletion of codons 678 and 679 in gyrB mutant gene assessed as microbial susceptibility by agar proportion m	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1413530	Toxicity in Staphylococcus aureus after 18 to 24 hrs by two-fold serial dilution method	2018	MedChemComm, Aug-01, Volume: 9, Issue:8	Design, synthesis, and biological evaluation of
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID396098	Antibacterial activity against Staphylococcus aureus K2361 overexpressing norA by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID295850	Antimicrobial activity against Proteus vulgaris A161 by disk diffusion method at 10 ug/disc	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID68183	Evaluated for minimum inhibitory concentration against gram-negative bacteria Enterobacter cloacae HA 2646	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID395358	Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID433583	Selectivity index, ratio of CC25 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to CC25 for Mycobacterium leprae wild type DNA gyrase A2B2 by DNA cleavage assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID510171	Antimicrobial activity against cephalosporin-resistant Enterococcus faecalis by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID428999	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT145 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID680399	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, OFLX: 1000 uM) in Xenopus laevis oocytes	1999	The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID559559	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1331870	Antibacterial activity against Listeria monocytogenes ATCC 19115	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID151194	Activity against Pseudomonas cepacia (IID-1341)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID560593	Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID563025	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1412152	Antibacterial activity against Pseudomonas aeruginosa isolate 1 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID563007	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1753998	Permeability of the compound in PBS/EtOH buffer (7:3) incubated for 16 hrs by UV plate reader based PAMPA-BBB assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1177574	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by microdilution method	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus.
AID133815	Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1230211	Antibacterial activity against Enterococcus avium CIP 104053 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID197875	Minimum inhibition concentration against Staphylococcus aureus FDA209P strain	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID530418	Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1295093	Toxicity in healthy mouse administered as single peroral dose measured after 14 days	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1326673	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID540228	Clearance in human after iv administration	2006	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7	Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID78695	Gyrase inhibitory activity against Escherichia coli	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID396102	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID429018	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG8 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID529669	Antimicrobial activity against Escherichia coli R4525 expressing gyrA S83L and D87Y and parC S80I and E84G mutant gene by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
AID530389	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID520868	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU28 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID1296386	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 1 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530399	Antimicrobial activity against Helicobacter pylori 1 harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID279842	Toxicity in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID352849	Antimicrobial activity against Lipomyces lipofer NCIM 3252 at 5 ug/disk after 72 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID530401	Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1113449	Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm)	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID78709	Inhibition of DNA gyrase of Escherichia coli H560 cells	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID165048	In vitro antibacterial activity against Pseudomonas aeruginosa IFO 3445	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID352093	Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID563028	Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1230237	Antibacterial activity against Staphylococcus aureus CIP 483 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1161578	Permeability of the compound by PAMPA-BBB assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID1163978	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
AID534340	Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID316444	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID563223	Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563037	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID69952	Antimicrobial activity against the Escherichia coli JUHL by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID386886	Antibacterial activity against sEscherichia coli ATCC 25922 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID563047	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID535843	Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID581492	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA A90V mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID428996	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT118 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1319976	Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1230242	Antibacterial activity against Staphylococcus aureus CRBIP 2121 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID143121	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 90%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID1557297	Half life in human at 0.4 g, po bid	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1636268	Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID563226	Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID64253	Activity against Escherichia coli (KC-14)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID428992	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 50 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1309356	Antimycobacterial activity against rifampin and isoniazid resistant-Mycobacterium tuberculosis Beijing harboring Ser 531 to Leu 315 and Ser to Thr in rpoB and katG genes mutation after 24 hrs by microbroth dilution method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.
AID447082	Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID1173449	Effective permeability of the compound by PAMPA assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID395097	Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID30399	Compound was tested for antibacterial activity against gram negative Acinetobacter calcoaceticus No.4	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID510166	Antimicrobial activity against Escherichia coli ATCC 35218 by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID1230206	Antibacterial activity against Bacillus cereus N190 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID574811	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID197994	Activity against Staphylococcus aureus (FDA207PJC-1)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID287378	Antibacterial activity against Listeria monocytogenes after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID1274480	Antibacterial activity against Proteus vulgaris ATCC 8427 after 24 hrs by two-fold serial dilution method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents.
AID322317	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID563220	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID531335	Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID530397	Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID467863	Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs	2009	Journal of natural products, Dec, Volume: 72, Issue:12	Structurally diverse limonoids from the fruits of Swietenia mahagoni.
AID405116	Antimicrobial activity against Escherichia coli TOP10 harbouring pVS1 expressing quinolone resistant Vibrio splendidus 12B01 QnrVS1 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID1435651	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID295118	Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID122925	Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Micrococcus luteus ATCC 9341 (MI)	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID1143263	Antimycobacterial activity against Mycobacterium tuberculosis Beijing (E-47/94) assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID581508	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D540D mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1743439	Antitubercular activity against Mycobacterium tuberculosis H37Rv measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID206216	Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus epidermidis IAM 1296 (Se)	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID391989	Antibacterial activity against Lactococcus lactis IL-1419 by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID559562	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID429031	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 21095 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1463960	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 234/2005 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID279824	Cmax in BALB/c mouse at 37.5 to 2400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID1143268	Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis 19000 assessed as growth inhibition after 2 to 3 weeks by turbidometry	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
AID656228	Antimycobacterial activity against isoniazid-, rifampin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID395779	Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID530395	Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID30416	Antimicrobial activity against the acinetobacter sp. CMX 669 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID371459	Antimicrobial activity against Staphylococcus aureus isolate after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID429009	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT47 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1224519	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID581512	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94A mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1378879	Effective permeability of the compound at 100 mg/ml after 16 hrs by UV based PAMPA-BBB assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID163227	Compound was tested for antibacterial activity against gram negative Proteus vulgaris KS-134	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID70566	Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(N), Escherichia coli NIHJ JC-2.	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID1360038	Antimicrobial activity against Bacillus cereus after 18 to 20 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID581498	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D540D mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID563214	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID206652	Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 90% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range)	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID131001	Compound was tested for oral efficacy on systemic infections caused by Escherichia coli KC-14 in mice	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1231419	Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of caracasine acid derivatives.
AID530373	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID562791	Antimicrobial activity against Chlamydia trachomatis F/70/rifR harboring rpoB gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1502711	Antimycobacterial activity against Mycobacterium avium isolate MAV2 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1201747	Permeability of the compound by PAMPA	2015	European journal of medicinal chemistry, May-05, Volume: 95	Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID1296384	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 9449/2007 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID386885	Antibacterial activity against Staphylococcus aureus ATCC 19433 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID391982	Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23::qnr-cat promoter mutant overexpressing qnr by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1743443	Antibacterial activity against Mycobacterium bovis BCG measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1653553	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.75 ug/ml in presence of 0.2 ug/ml rifampin measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID1152780	Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates after 2 to 4 weeks by BACTEC 460 radiometric assay	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1435649	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 14 days by micromethod	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
AID385167	Antimicrobial activity against Bacillus cereus by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID682301	TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, OFLX: 500 uM) in OCTN2-expressing HEK293 cells	1999	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2	Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID1230233	Antibacterial activity against Listeria monocytogenes N836 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID557095	Binding affinity to first site on human serum albumin by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1743445	Antibacterial activity against Acinetobacter baumannii measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID206684	Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pneumoniae SV-1	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID530416	Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID562796	Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR2 harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID530246	Antimicrobial activity against surA deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli.
AID1230222	Antibacterial activity against Enterococcus faecium N490 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID562799	Antimicrobial activity against Chlamydia muridarum MoPn/tetR1 harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID428980	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate A102 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID557097	Protein binding in serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1352675	Effective permeability at 25 ug/ml after 18 hrs by PAMPA	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID713896	Antimycobacterial activity against Mycobacterium tuberculosis isolate CIBIN/UMF 15:19	2012	European journal of medicinal chemistry, Mar, Volume: 49	Recent advances in antitubercular natural products.
AID69826	Tested in vitro against Escherichia coli NIHJ JC-2 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1349195	Antichlamydial activity against Chlamydia trachomatis serovar D 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis.
AID316446	Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
AID428983	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT61 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID713895	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294	2012	European journal of medicinal chemistry, Mar, Volume: 49	Recent advances in antitubercular natural products.
AID520874	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU90 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID1557296	AUC in human at 0.4 g, po bid	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID572518	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2705 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID559372	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1071344	Permeability of the compound by BBB-PAMPA	2014	European journal of medicinal chemistry, Feb-12, Volume: 73	1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID1915642	Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 (H37Rv) assessed as reduction in bacterial growth incubated for 14 days by microdilution method	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
AID1230230	Antibacterial activity against Listeria innocua E044 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID530382	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1577335	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 234/2005 after 14 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID143862	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 90%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID563014	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1230240	Antibacterial activity against Staphylococcus aureus CIP 5710 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID1516021	Antibacterial activity against Salmonella enterica serovar typhimurium C77-31 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID530400	Antimicrobial activity against Helicobacter pylori 2 harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1695810	Antibacterial activity against Staphylococcus aureus assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
AID68191	In vitro antibacterial activity against Enterobacter cloacae 963	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID498786	Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID1230239	Antibacterial activity against Staphylococcus aureus CIP 53156 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID203317	In vitro antibacterial activity against Serratia marcescens IFO 3736	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1193923	Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID395773	Antibacterial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID530393	Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID429014	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG3 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1412147	Antibacterial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID1230205	Antibacterial activity against Bacillus cereus CIP 6624 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID425070	Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID287372	Antibacterial activity against Staphylococcus aureus after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID559551	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1393806	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by broth dilution assay relative to control	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Fluoroquinolone derivatives and their anti-tubercular activities.
AID1907631	Antibacterial activity against Pseudomonas aeruginosa incubated for 18 to 20 hrs by double dilution method	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.
AID429015	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG5 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID433579	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID78705	Inhibition constant against DNA Gyrase isolated from Escherichia coli	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID163785	Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (E-2)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID133953	In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered perorally	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.
AID131005	Compound was tested for oral efficacy on systemic infections on mice by peroral administration	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID639368	Permeability of the compound by PAMPA assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID1703887	Permeability of the compound incubated for 165 mins by PAMPA-BBB assay	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID143108	Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 50%	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID510162	Antimicrobial activity against trimethoprim-sulfamethoxazole and tazobactum-induced Pseudomonas aeruginosa by spectrophotometry	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
AID395362	Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
AID391977	Antibacterial activity against Enterococcus faecalis JH2-2 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1188154	Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID530368	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID762021	Antibacterial activity against Staphylococcus aureus 209p measured every 24 hrs for 5 days by conventional dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety.
AID530415	Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1227981	Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Ra assessed as microbial growth inhibition incubated at 37 degC for 7 days by fluorescence based assay	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Eremophilane Sesquiterpenes and Diphenyl Thioethers from the Soil Fungus Penicillium copticola PSU-RSPG138.
AID352625	Antimicrobial activity against Klebsiella aerogenes NCIM 2239 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID1056993	Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID442657	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives.
AID352633	Antimicrobial activity against Escherichia coli NCIM 2065 at 5 ug/disk after 24 hrs by disk diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives.
AID425071	Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID287374	Antibacterial activity against Bacillus cereus after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID74853	Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB)	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
AID71793	Percentage of GABA-induced chloride currents with 10 e-5 M 4-biphenylacetic acid	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID396096	Antibacterial activity against Staphylococcus aureus K1758-A overexpressing mepA by broth microdilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID429019	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG15 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID69784	Antibacterial activity against Escherichia coli (vogel)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1743459	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ser-91-Pro mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID205650	Compound was tested for antibacterial activity against gram positive Staphylococcus aureus FDA 209P JC-1	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID581501	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID38471	Activity against Bacillus subtilis (ATCC 6633)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID1412151	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by microbroth dilution method	2018	MedChemComm, Jan-01, Volume: 9, Issue:1	Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.
AID279827	AUC(0-infinity) in BALB/c mouse at 37.5 to 2400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID1230234	Antibacterial activity against Listeria monocytogenes N851 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID563210	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID447083	Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID515780	Intrinsic solubility of the compound in water	2010	Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19	QSAR-based solubility model for drug-like compounds.
AID1360042	Bactericidal activity against Staphylococcus aureus after 24 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID563057	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID162776	In vitro minimum inhibitory concentration against Pseudomonas aeruginosa E-2	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID535848	Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID562790	Antimicrobial activity against Chlamydia trachomatis J/6276/tetR harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1321386	Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method	2016	Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19	The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases.
AID279822	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 7	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID1502713	Antimycobacterial activity against Mycobacterium avium isolate MAV4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1437019	Antimycobacterial activity against isoniazid/rifampicin/ethambutol-sensitive Mycobacterium tuberculosis H37Rv after 4 days by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives.
AID1672291	Antifungal activity against Candida tropicalis assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay
AID70426	Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RE45	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID433582	Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID523004	Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID763994	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by two-fold serial dilution method	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
AID498785	Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID70804	Inhibition of growth of Escherichia coli vogel	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID65376	Tested in vitro for antibacterial activity agains Enterococcus faecalis (IID 682)	1993	Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID1480943	Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID322315	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID581514	Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G and D94A mutant genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID563020	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID209278	Antimicrobial activity against the streptococcus pyogenes 2548 by 2-fold agar dilution method using brain-heart infusion agar.	1987	Journal of medicinal chemistry, Dec, Volume: 30, Issue:12	Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
AID96239	Evaluated for minimum inhibitory concentration against gram-negative bacteria Klebsiella pneumoniae MGH-2	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID562795	Antimicrobial activity against Chlamydia muridarum MoPn/oflR-rifR harboring ompA and rpoB genes	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID1463959	Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 9449/2007 incubated for 14 days by micromethod	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
AID1163981	Cytotoxicity against mouse RAW264.7 cells at 100 uM after 72 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID164565	Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa AK109	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID1502707	Antimycobacterial activity against Mycobacterium avium 104 mc'2 3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID563213	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1224517	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
AID1331877	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID1368749	Antibacterial activity against Bacillus subtilis MTCC 441 at 1 ug/ml under overnight incubation condition by paper disc method	2018	Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2	Synthesis and biological evaluation of 1-amino isochromans from 2-bromoethyl benzaldehyde and amines in acid medium.
AID371458	Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID563021	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID295851	Antimicrobial activity against Proteus vulgaris KUKEM1329 by disk diffusion method at 10 ug/disc	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID1296387	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 4 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID162792	Inhibition of growth of Pseudomonas aeruginosa	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID287373	Antibacterial activity against Klebsiella pneumoniae after 72 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Feb, Volume: 42, Issue:2	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
AID1413648	Antibacterial activity against methicillin-resistant Staphylococcus aureus JCSC 4788 at sub-MIC re-passaged at 24 hrs intervals for 5 times by micro dilution susceptibility test	2018	MedChemComm, Oct-01, Volume: 9, Issue:10	Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.
AID164245	Antibacterial activity against Pseudomonas aeruginosa UI-18	1988	Journal of medicinal chemistry, Mar, Volume: 31, Issue:3	7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID295852	Antimicrobial activity against Streptococcus pyogenes ATCC 176 by disk diffusion method at 10 ug/disc	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID208893	Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1331875	Antibacterial activity against Escherichia coli MC1061	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.
AID1413531	Toxicity in Escherichia coli after 18 to 24 hrs by two-fold serial dilution method	2018	MedChemComm, Aug-01, Volume: 9, Issue:8	Design, synthesis, and biological evaluation of
AID203326	In vitro antibacterial activity against Serratia marcescens S-9	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
AID562826	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID428997	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT142 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID563053	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1516025	Antibacterial activity against Escherichia coli 20411 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID52938	Compound was tested for antibacterial activity against gram negative Citrobacter freundii No.7	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID1593374	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in multidrug-resistant Mycobacterium tuberculosis V2475 assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID371466	Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID535839	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID563044	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562789	Antimicrobial activity against Chlamydia trachomatis L2/tetR13 harboring tet(C) allele	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.
AID391978	Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT mutant with inactivated qnr gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID559553	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID563019	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID197995	Activity against Staphylococcus aureus (IID 803)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids.
AID562946	Upregulation of slpA gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID563022	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563335	Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID572515	Antimicrobial activity against Salmonella enterica serovar Stanley isolate s2043 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID532989	Antibacterial activity against Klebsiella aerogenes NCIM 2281 in presence of 10 mM N-Acetylcysteine	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID563054	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID395716	Antibacterial activity against Escherichia coli DH10B by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1360044	Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by micro broth dilution method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents.
AID1577337	Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 7357/1998 after 21 days	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
AID562825	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID550049	Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of visible growth after 48 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID530404	Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrA QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID151535	Tested in vitro against Pseudomonas aeruginosa E-2 by agar dilution method	1993	Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19	Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones.
AID1516085	Antibacterial activity against ciprofloxacin-resistant Escherichia coli ATCC 25922 incubated for 18 to 24 hrs	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID562936	Upregulation of cwp84 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID563008	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562938	Upregulation of cwp84 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID581496	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94Y mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1326672	Growth inhibition of mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID1765292	Permeability of compound by PAMPA-BBB assay	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID425074	Antimicrobial activity against Escherichia coli DH10B in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID1309355	Antimycobacterial activity against Mycobacterium terrae after 24 hrs by microbroth dilution method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.
AID1557298	Protein binding in human at 0.4 g, po bid	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1653554	Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.025 ug/ml rifabutin measured at 4 weeks (Rvb = 147 +/- 19.1%)	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID1326670	Inhibition of Mycobacterium smegmatis 155 6His-tagged DNA gyrase B catalytic domain ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as inorganic phosphate release after 120 mins in presence of ATP by malachite green dye based	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID324746	Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID530374	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID557090	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID391980	Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23 promoter by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID572509	Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate SL1344 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID405477	Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 5 ug by disc diffusion method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.
AID530381	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1172969	Antibacterial activity against Escherichia coli TG1	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity.
AID656229	Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
AID429020	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG16 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1230231	Antibacterial activity against Listeria monocytogenes CIP 103575 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID562941	Effect on fbp69 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID530375	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID391975	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID559369	Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID572521	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2209 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1516022	Antibacterial activity against Escherichia coli UB1005 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID531333	Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID405478	Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 30 ug by disc diffusion method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427196	Membrane permeability by PAMPA-BBB assay	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1890597	Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1296383	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 234/2005 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID395777	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by twofold serial dilution technique	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles.
AID208894	Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID293586	Antibacterial activity against Staphylococcus aureus isolate assessed after 24 hrs by serial dilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.
AID391986	Antibacterial activity against Staphylococcus aureus RN4220 by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID563101	Upregulation of fbp68 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID428977	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate D43 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID385163	Antimicrobial activity against Escherichia coli by broth microdilution method	2008	Journal of natural products, Apr, Volume: 71, Issue:4	Antimicrobial triterpenoids from Vladimiria muliensis.
AID535832	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID563227	Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1743446	Antibacterial activity against Enterobacter aerogenes measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID442659	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives.
AID563342	Induction of Cwp84 protease expression in Clostridium difficile CD07-259 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID562827	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1231421	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of caracasine acid derivatives.
AID1230232	Antibacterial activity against Listeria monocytogenes N783 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID447081	Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID205653	Compound was tested for antibacterial activity against gram positive Staphylococcus aureus smith	1998	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20	Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones.
AID206009	Minimum inhibitory concentration required in vitro against Staphylococcus aureus	1999	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.
AID563501	Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.
AID210022	Antibacterial activity against Streptococcus pneumoniae (SV-1)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1502708	Antimycobacterial activity against Mycobacterium avium 104 mc'2 4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID563034	Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1301200	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 10 days by micro broth dilution method	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.
AID530420	Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID209240	Inhibition of growth of Streptococcus faecalis	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1.
AID559370	Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID1126742	Antibacterial activity against 1 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID581495	Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94N mutant gene	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
AID1230248	Antibacterial activity against Staphylococcus saprophyticus E260 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID429008	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT42 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID429029	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID405470	Antibacterial activity against oxacillin-dependent methicillin-resistant Staphylococcus aureus 2884D isolate at 5 ug by disc diffusion method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.
AID572524	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Stanley isolate s2018 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID563011	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID123085	In vitro antibacterial activity against Micrococcus luteus ATCC 9341	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1296385	Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days by microdilution method	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
AID428981	Antimicrobial activity against Salmonella enterica Serovar Typhi isolate C152 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID1167605	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold agar dilution method	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
AID1230209	Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by agar dilution method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Antibacterial Labdane Diterpenoids from Vitex vestita.
AID535847	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID522870	Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 400 to 700 ug/ml after 12 hrs by serial dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
AID428989	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 28 harboring DNA gyrase A S83F mutation by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID96421	In vitro minimum inhibitory concentration against Klebsiella pneumoniae B54	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID560260	Antimicrobial activity against Salmonella enterica serovar Typhimurium transconjugant p61/9T expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID534419	Antibacterial activity against Mycobacterium bovis BCG-Connaught	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
AID447217	Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by agar disk diffusion assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
AID67422	In vitro minimum inhibitory concentration against E. Faecalis IID682	1993	Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18	Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.
AID164713	Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa IFO 3445 (Pa(I))	1994	Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17	Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2.
AID563013	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID530425	Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1326671	Inhibition of Mycobacterium tuberculosis DNA gyrase subunit A2B2 supercoiling activity using relaxed pBR322 as substrate after 30 mins in presence of ATP by agarose gel electrophoresis	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID733006	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electro	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID1183278	Permeability of the compound by PAMPA	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID110153	Percentage of mice with convulsion with compound alone at 400 mg/kg	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships.
AID429032	Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 3769 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
AID70721	Evaluated for minimum concentration needed to produce linear DNA at an intensity relative to oxolinic acid at 10 mg/mL. by gyrase mediated cleavage of DNA in Escherichia coli 560.	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships.
AID559560	Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
AID371465	Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by disk diffusion method	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Synthesis and biological activity of some new benzoxazoles.
AID530621	Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrB QRDR	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1177576	Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs by microdilution method	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus.
AID559582	Antimicrobial activity against Chlamydophila psittaci infected in Vero cells	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.
AID391976	Antibacterial activity against Escherichia coli ATCC 25922 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1900247	Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
AID295106	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method	2007	European journal of medicinal chemistry, Aug, Volume: 42, Issue:8	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
AID1152778	Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis harboring DNA gyraseA G88N mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1177577	Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by microdilution method	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	679 (11.20)	18.7374
1990's	1543 (25.45)	18.2507
2000's	2270 (37.45)	29.6817
2010's	1307 (21.56)	24.3611
2020's	263 (4.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	976 (15.05%)	5.53%
Reviews	333 (5.14%)	6.00%
Case Studies	782 (12.06%)	4.05%
Observational	6 (0.09%)	0.25%
Other	4,387 (67.66%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma[NCT00002850]	Phase 3	212 participants (Actual)	Interventional	1997-03-31	Completed
Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study[NCT01353339]	Phase 4	154 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers[NCT00659646]	Phase 2	56 participants (Actual)	Interventional	2008-04-30	Completed
Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Standard Treatment[NCT03698682]	Phase 2	310 participants (Actual)	Interventional	2018-01-01	Completed
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial[NCT03658746]	Phase 4	420 participants (Actual)	Interventional	2019-01-01	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics[NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for [NCT03739528]	Phase 3	808 participants (Actual)	Interventional	2018-09-03	Completed
A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as [NCT02439632]	Phase 3	216 participants (Anticipated)	Interventional	2014-02-28	Completed
Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy (PCNL)[NCT03178292]		300 participants (Anticipated)	Interventional	2017-06-15	Not yet recruiting
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori[NCT02422706]	Phase 3	120 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection and Its Influence on Recurrence Rate: a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study[NCT03658291]	Phase 4	252 participants (Anticipated)	Interventional	2019-01-01	Not yet recruiting
Efficacies of Tetracycline-levofloxacin Quadruple Therapy, Standard Bismuth Quadruple Therapy and Amoxicillin-levofloxacin Quadruple Therapy in the Second-line Treatment of H Pylori Infection[NCT05850117]		240 participants (Anticipated)	Interventional	2020-02-10	Recruiting
Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Treatment Guided by Markers of Inflammation[NCT02067780]	Phase 3	310 participants (Actual)	Interventional	2017-05-01	Completed
Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)[NCT00578474]	Phase 3	911 participants (Actual)	Interventional	2005-12-31	Completed
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers[NCT02128308]	Phase 1	16 participants (Actual)	Interventional	2013-11-30	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants[NCT01349738]		200 participants (Anticipated)	Observational	2011-05-31	Enrolling by invitation
Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection[NCT04496024]		110 participants (Anticipated)	Interventional	2020-06-02	Recruiting
Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144]	Phase 3	60 participants (Anticipated)	Interventional	2017-07-07	Recruiting
VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia[NCT02528123]		187 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials[NCT05863858]	Phase 3	162 participants (Actual)	Interventional	2020-06-01	Completed
Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis[NCT00621387]		56 participants (Actual)	Interventional	1993-11-30	Completed
Comparison of the Effectiveness of Preurodynamic Single Dose of Levofloxacin With Posturodynamic Levofloxacin for Three Days on the Incidence of Urinary Tract Infections[NCT05219877]	Phase 1/Phase 2	134 participants (Actual)	Interventional	2022-02-04	Completed
[NCT02157571]	Phase 3	360 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Evaluation of Lactated Ringers for Protection From Cisplatin Ototoxicity.[NCT00584155]	Phase 1	0 participants (Actual)	Interventional	2006-07-31	Withdrawn(stopped due to PI left the university.)
A Phase II, Multi-Center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW 1201 Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis[NCT05816070]	Phase 2	129 participants (Actual)	Interventional	2023-01-05	Completed
Evaluation of the Congruity of Methods Used in the Diagnostics of Chronic Endometritis in the Course of Infertility and the Effectiveness of Antibiotic Therapy in the Context of Remission of Symptoms and Obstetric Results[NCT05946655]		100 participants (Actual)	Interventional	2021-04-01	Completed
A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis[NCT00402688]	Phase 3	242 participants (Actual)	Interventional	2006-11-30	Completed
Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction[NCT02540785]		41 participants (Actual)	Interventional	2014-04-30	Completed
Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic [NCT00683865]	Phase 3	749 participants (Actual)	Interventional	2003-04-30	Completed
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media[NCT02567825]		250 participants (Actual)	Interventional	2015-11-30	Completed
Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery[NCT03655665]	Phase 4	125 participants (Anticipated)	Interventional	2019-05-16	Recruiting
A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes[NCT00781521]	Phase 3	96 participants (Actual)	Interventional	2002-11-30	Completed
A Randomized, Double-masked, Parallel Group Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery (Levofloxacin 0.5% Ophthalmic Solution as a Comparator) - Phase III, Confirmatory Study of Perioperative Bacteria Eradicatio[NCT02573610]	Phase 3	576 participants (Actual)	Interventional	2015-09-21	Completed
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563394]	Phase 3	584 participants (Actual)	Interventional	1994-08-31	Completed
Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis.[NCT00873626]	Phase 4	310 participants (Actual)	Interventional	2009-06-30	Completed
Phase 4 Study of Azitromicin in the Treatment of PID[NCT01241110]	Phase 4	100 participants (Actual)	Interventional	2010-01-31	Completed
Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation[NCT05743101]		80 participants (Anticipated)	Interventional	2023-02-13	Not yet recruiting
Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs[NCT00392275]	Phase 4	48 participants	Interventional	2002-11-30	Completed
An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections[NCT00516958]	Phase 2	65 participants (Anticipated)	Interventional	2007-05-31	Completed
Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis[NCT02551796]		75 participants (Actual)	Interventional	2015-09-30	Completed
Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach[NCT00250718]	Phase 2	17 participants (Actual)	Interventional	2004-10-31	Terminated(stopped due to Low rate of accrual)
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study[NCT05126121]		60 participants (Anticipated)	Interventional	2021-11-20	Not yet recruiting
Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke[NCT05741905]		100 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy[NCT04502095]	Phase 4	100 participants (Anticipated)	Interventional	2020-09-02	Recruiting
Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.[NCT02726269]	Phase 3	230 participants (Actual)	Interventional	2012-06-30	Completed
An Open-label, Randomized, 3-way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects[NCT00602589]	Phase 1	72 participants (Actual)	Interventional	2002-10-31	Completed
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563433]	Phase 3	342 participants (Actual)	Interventional	1994-08-31	Completed
Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial[NCT05549115]		500 participants (Anticipated)	Interventional	2022-09-20	Recruiting
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis[NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment[NCT02988089]	Phase 4	480 participants (Anticipated)	Interventional	2017-04-20	Recruiting
Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate[NCT00480376]	Phase 4	160 participants (Anticipated)	Interventional	2007-06-30	Not yet recruiting
A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis[NCT00565123]	Phase 2/Phase 3	119 participants (Actual)	Interventional	2004-09-30	Completed
Effect of Nasal Ointment on Epistaxis of Nasotracheal Intubation in Children: A Randomized Controlled Trial[NCT04426409]		108 participants (Actual)	Interventional	2020-07-08	Completed
Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT01537055]	Phase 4	600 participants (Anticipated)	Interventional	2012-02-29	Recruiting
A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)[NCT01537250]	Phase 2	192 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxa[NCT00035347]	Phase 4	219 participants (Actual)	Interventional	2001-01-31	Completed
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012]		51 participants (Actual)	Interventional	2013-11-30	Completed
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients[NCT01573910]	Phase 3	985 participants (Actual)	Interventional	2012-05-31	Completed
Treatment of Methicillin-sensitive Staphylococcus Aureus Orthopaedic Infections With Clindamycin in Combination With Rifampin or Levofloxacin: a Randomized Pharmacological and Clinical Study (the CLINDOS Trial)[NCT01500837]		23 participants (Actual)	Interventional	2010-10-31	Completed
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure[NCT04810793]		820 participants (Actual)	Observational [Patient Registry]	2020-07-01	Completed
A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery[NCT03933631]	Phase 3	142 participants (Anticipated)	Interventional	2019-05-01	Recruiting
"A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients."[NCT01761201]	Phase 3	68 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to Recruitment rythm not sufficent to reach the simple size needed.)
An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201]	Phase 3	402 participants (Actual)	Interventional	2019-08-22	Active, not recruiting
A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157]		102 participants (Actual)	Interventional	2015-02-28	Completed
Descemet Endothelial Thickness Comparison Trial[NCT02373137]	Phase 4	38 participants (Actual)	Interventional	2015-01-22	Active, not recruiting
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial[NCT05799326]		100 participants (Anticipated)	Interventional	2023-06-30	Recruiting
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia[NCT03551210]	Phase 3	342 participants (Actual)	Interventional	2016-05-04	Completed
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection - a Multi-center Randomized Controlled Trial[NCT03779087]		112 participants (Actual)	Interventional	2018-07-11	Completed
Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan[NCT03832465]	Phase 4	20 participants (Actual)	Interventional	2019-06-14	Completed
[NCT01799356]	Phase 4	1,303 participants (Actual)	Interventional	2010-06-30	Completed
The Usefulness of Melatonin Supplementation in Postmenopausal Women With Helicobacter Pylori-associated Dyspepsia[NCT04352062]		152 participants (Actual)	Interventional	2011-01-09	Completed
A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Trabectome Surgery[NCT04005079]	Phase 3	0 participants (Actual)	Interventional	2019-06-05	Withdrawn(stopped due to not performing Trabectomes)
Personalized Treatment for Refractory H Pylori Infection[NCT02547025]		126 participants (Actual)	Interventional	2012-08-01	Completed
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial[NCT02424461]	Phase 3	400 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Aqueous Humour Concentrations After Topical apPlication of combinEd Levofloxacin-dexamethasone Eye dRops and of Its Single Components: a randoMized, assEssor-blinded, Parallel-group Study in Patients Undergoing Cataract Surgery - iPERME[NCT03740659]	Phase 2	125 participants (Actual)	Interventional	2018-09-04	Completed
An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections[NCT03160807]	Phase 4	214 participants (Anticipated)	Interventional	2017-04-15	Recruiting
Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model[NCT02357407]	Phase 4	31 participants (Actual)	Interventional	2015-06-30	Completed
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori.[NCT01575899]	Phase 4	208 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Early termination due to efficacy)
Comparison of Ofloxacin and Metronidazole/Amoxicillin on the Treatment of Periodontitis.[NCT04353362]	Phase 4	74 participants (Actual)	Interventional	2017-04-01	Completed
Bioequivalence Study of Levomerc (Levofloxacin) 500 mg Tablet With Tavanic (Levofloxacin) 500 mg Tablets[NCT05339295]	Phase 1	24 participants (Actual)	Interventional	2012-07-11	Completed
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections[NCT03378427]		35 participants (Actual)	Interventional	2018-08-28	Completed
Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients[NCT01270347]	Phase 3	267 participants (Actual)	Interventional	2011-01-31	Completed
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis[NCT05398679]	Phase 4	360 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations[NCT01988779]	Phase 3	33 participants (Actual)	Interventional	2013-10-31	Completed
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study[NCT05302531]	Phase 1	10 participants (Anticipated)	Interventional	2022-12-09	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Ciprofloxacin or Ofloxacin	12.5
TMP-SMX	6.8
No Prophylaxis	15.9

Intervention	Participants (Count of Participants)
Gentamicin Sponge	0
Levofloxacin	3

Intervention	cm^2 (Mean)
	Visit 1 Day 1	Visit 2 Day 3	Visit 3 Day 7	Visit 4 Day 10	Visit 5 Day 14	Visit 6 Day 21	Visit 7 Day 28	Final Study Visit Day 42
Gentamicin Sponge	5.11	4.50	4.47	4.31	4.14	2.93	2.67	3.73
No Sponge	1.24	.92	.76	1.14	0.95	1	.93	.64

Intervention	Participants (Count of Participants)
	Patients with TEAEs	Patients with serious TEAEs	Patients with TEAEs suspected to be study related	Patients with TEAEs leading to discontinuation	Patients with fatal TEAEs	Patients with severe TEAEs
Levofloxacin + Dexamethasone Followed by Dexamethasone	56	4	26	4	1	3
Tobramycin + Dexamethasone	51	2	26	3	0	0

Intervention	score on a scale (Mean)
	Burning: visit 3 - day 4	Burning: visit 4 - day 8	Burning: visit 5 - day 15	Stinging: visit 3 - day 4	Stinging: visit 4 - day 8	Stinging: visit 5 - day 15	Blurred vision: visit 3 - day 4	Blurred vision: visit 4 - day 8	Blurred vision: visit 5 - day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.08	0.06	0.07	0.05	0.07	0.06	0.06	0.06	0.03
Tobramycin + Dexamethasone	0.09	0.11	0.07	0.04	0.07	0.04	0.05	0.04	0.01

Intervention	score on a scale (Mean)
	Visit 3 - Day 4	Visit 4 - Day 8	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.03	0.01	0.02
Tobramycin + Dexamethasone	0.01	0.03	0.02

Intervention	mmHg (Mean)
	Visit 1 - Screening	Visit 3 - Day 4	Visit 4 - Day 8	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	15.16	14.26	14.29	14.45
Tobramycin + Dexamethasone	15.12	14.49	14.45	14.37

Intervention	Participants (Count of Participants)
	Visit 3 - Day 4: no diagnosis of endophthalmitis	Visit 4 - Day 8: no diagnosis of endophthalmitis	Visit 5 - Day 15: no diagnosis of endophthalmitis
Levofloxacin + Dexamethasone Followed by Dexamethasone	393	391	389
Tobramycin + Dexamethasone	393	393	391

Intervention	Participants (Count of Participants)
	Visit 3 - Day 472467252		Visit 3 - Day 472467251	Visit 4 - Day 872467251	Visit 4 - Day 872467252	Visit 5 - Day 1572467252	Visit 5 - Day 1572467251
	Score>0	Score=0
Levofloxacin + Dexamethasone Followed by Dexamethasone	337
Tobramycin + Dexamethasone	323
Levofloxacin + Dexamethasone Followed by Dexamethasone	58
Tobramycin + Dexamethasone	70
Levofloxacin + Dexamethasone Followed by Dexamethasone	348
Tobramycin + Dexamethasone	358
Levofloxacin + Dexamethasone Followed by Dexamethasone	47
Tobramycin + Dexamethasone	35
Levofloxacin + Dexamethasone Followed by Dexamethasone	371
Tobramycin + Dexamethasone	375
Levofloxacin + Dexamethasone Followed by Dexamethasone	24
Tobramycin + Dexamethasone	18

Intervention	Participants (Count of Participants)
	Visit 1 - Screening72467251		Visit 1 - Screening72467252	Visit 3 - Day 472467252	Visit 3 - Day 472467251	Visit 4 - Day 872467252	Visit 4 - Day 872467251
	Number of participants without signs	Number of participants with signs
Levofloxacin + Dexamethasone Followed by Dexamethasone	395
Tobramycin + Dexamethasone	393
Levofloxacin + Dexamethasone Followed by Dexamethasone	0
Tobramycin + Dexamethasone	0
Levofloxacin + Dexamethasone Followed by Dexamethasone	289
Tobramycin + Dexamethasone	302
Levofloxacin + Dexamethasone Followed by Dexamethasone	106
Tobramycin + Dexamethasone	91
Levofloxacin + Dexamethasone Followed by Dexamethasone	338
Tobramycin + Dexamethasone	341
Levofloxacin + Dexamethasone Followed by Dexamethasone	57
Tobramycin + Dexamethasone	52

Intervention	Participants (Count of Participants)
	Visit 3 - Day 4: Presence/absence of ocular pain72467252		Visit 3 - Day 4: Presence/absence of ocular pain72467251	Visit 4 - Day 8: Presence/absence of ocular pain72467251	Visit 4 - Day 8: Presence/absence of ocular pain72467252	Visit 5 - Day 15: Presence/absence of ocular pain72467252	Visit 5 - Day 15: Presence/absence of ocular pain72467251
	Score=0	Score>0
Levofloxacin + Dexamethasone Followed by Dexamethasone	360
Tobramycin + Dexamethasone	361
Levofloxacin + Dexamethasone Followed by Dexamethasone	35
Tobramycin + Dexamethasone	32
Levofloxacin + Dexamethasone Followed by Dexamethasone	366
Tobramycin + Dexamethasone	366
Levofloxacin + Dexamethasone Followed by Dexamethasone	29
Tobramycin + Dexamethasone	27
Levofloxacin + Dexamethasone Followed by Dexamethasone	377
Tobramycin + Dexamethasone	373
Levofloxacin + Dexamethasone Followed by Dexamethasone	18
Tobramycin + Dexamethasone	20

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	pg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG	604
LPV/RTV 400/100 b.i.d. With ENG	428
EFV 600mg q.d. With ENG	125

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	Participants (Count of Participants)
	3rd Trimester	Postpartum
EFV 600mg q.d.	20	21
MVC 150 or 300mg b.i.d.	8	7

Intervention	Participants (Count of Participants)
	2nd Trimester	3rd Trimester	Postpartum
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	8	29	27
DRV/COBI 800/150 mg q.d.	3	4	14
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	7	16	22
DRV/RTV 600/100mg b.i.d.	7	19	22
DRV/RTV 800/100mg q.d.	9	19	22
DTG 50mg q.d.	9	20	23
EFV 600 mg q.d. (Outside THA)	12	33	34
ATV/COBI 300/150 mg q.d.	1	2	5
ETR 200mg b.i.d.	5	13	7
EVG/COBI 150/150mg q.d.	8	10	18
FPV/RTV 700/100mg b.i.d.	8	26	22
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	10	19	26
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	9	30	27
ATV/RTV Arm 1: 300/100mg q.d.	1	12	12
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	NA	15	14
RAL 400mg b.i.d.	11	33	30
RPV 25mg q.d.	14	26	25
TAF 10mg q.d. w/COBI	15	23	22
TAF 25mg q.d.	13	23	24
TAF 25mg q.d. w/COBI or RTV Boosting	10	24	18
TFV 300mg q.d.	2	27	27
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.	1	11	12
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	7	23	32

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	Participants (Number)
Levofloxacin 750mg for 2 Weeks	46
Levofloxacin 750mg for 3 Weeks	48
Levofloxacin 500mg for 4 Weeks	52

Intervention	Participants (Number)
	Clinical Success	Failure	Unable to Evaluate	Missing
Levofloxacin 500mg for 4 Weeks	38	4	1	9
Levofloxacin 750mg for 2 Weeks	30	8	0	8
Levofloxacin 750mg for 3 Weeks	24	6	1	17

Intervention	Participants (Number)
	Dysuria (n=35, 43, 42)	Suprapubic discomfort (n=41, 36, 45)	Painful ejaculation (n=32, 39, 34)	Low back pain (n=43, 44, 44)	Perineal discomfort (n=40, 42, 50)	Frequency (n=58, 63, 62)	Urgency (n=48, 52, 58)	Hesitancy (n=37, 39, 54)	Decreased urinary stream (n=50, 47, 52)	Urinary retention (n=24, 26, 27)	Pain on digital rectal examination (n=60, 59, 61)	Perineal tenderness or pain (n=44, 38, 43)	Chills (n=4, 5, 7)	Other (n=5, 8, 8)	Fever (n=3, 2, 1)
Levofloxacin 500mg for 4 Weeks	27	30	20	26	29	30	35	38	30	17	42	28	7	5	1
Levofloxacin 750mg for 2 Weeks	23	24	17	20	20	29	20	19	24	13	30	28	3	1	2
Levofloxacin 750mg for 3 Weeks	29	19	23	22	19	24	28	16	21	13	30	24	3	5	2

Intervention	Score on a scale (Mean)
	Screening/Admission (n=73, 74, 75)	On-Therapy (n=70, 70, 73)	Week 3 (Visit 2) (n=62, 65, 68)	Week 4 (Visit 3) (n=53, 57, 61)	Posttherapy (Visit 4) (n=70, 71, 71)
Levofloxacin 500mg for 4 Weeks	12.9	6.9	5.6	4.5	4.6
Levofloxacin 750mg for 2 Weeks	11.8	7.2	6.5	5.1	5.4
Levofloxacin 750mg for 3 Weeks	12.0	6.6	6.5	4.9	5.0

Intervention	Score on a scale (Mean)
	Caregiver impact questionnaire score	Caregiver impact questionnaire--Caregiver's overall QOL score
Non-Surgical Management	10.93	8.50
Surgical Management	10.82	8.55

ofloxacin

Description

Cross-References

Synonyms (251)

Research Excerpts

Overview

Effects

Actions

Treatment

Drug Classes (5)

Protein Targets (46)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (75)

Molecular Functions (50)

Ceullar Components (32)

Bioassays (1631)

Research

Studies (6,062)

Study Types

Clinical Trials (86)

Trial Overview

Trial Outcomes

Proportion of Patients Experiencing a Serious Bacterial Infection

Number of Participants With a Clinical Cure at Visit 3 (Day 7)

Time to Clinical Cure

Change From Baseline in Total Wound Surface Area Measured in cm^2

Lipsky Wound Score

Number of Participants With a Clinical Cure at Each Visit Except Visit 3 (Day 7)

Number of Participants With a Positive Clinical Response at Each Time Point

Number of Participants With Pathogen Eradication by Visit

Visual Analog Scale (VAS) for Pain Assessment

Adverse Events

Burning, Stinging, Blurred Vision

Global Evaluation of Local Tolerability

Intraocular Pressure (IOP)

Number of Participants With Endophthalmitis

Total Ocular Symptoms Score (TOSS)

Visual Acuity

Conjunctival Hyperemia

Number of Participants Without Signs of Anterior Ocular Chamber Inflammation

Ocular Pain/Discomfort: 4-point Scale

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Plasma Concentration for Contraceptives

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Number of Participant With Urinary Tract Infection

Clinical Success

Clinical Success (Non-Relapse) or Failure (Relapse)

Clinical Success (Non-Relapse) or Failure (Relapse)

Clinical Success (Non-Relapse) or Failure (Relapse)

Symptom Relief (Resolved)

Total NIH-CPSI Score

The Mean Days Per Year Children Experience AOM Symptoms With an Intact Tympanic Membrane (TM)

The Mean Days Per Year Children Experience Tube Otorrhea

The Mean Days Per Year Children Receive Systemic Antimicrobials for AOM

Intervention	Score on a scale (Mean)
	OM-6 survey score	OM-6 survey--Children's overall QOL score
Non-Surgical Management	1.55	8.37
Surgical Management	1.5	8.45

Intervention	Occurrences per child-year (Mean)
	Children considered at low risk of AOM recurrence	Children considered at high risk of AOM recurrence
Non-Surgical Management	1.56	1.56
Surgical Management	1.28	1.67

Intervention	Participants (Count of Participants)
	No pathogens at enrollment72440667		No pathogens at enrollment72440668	Positive only for at least 1 penicillin-susceptible pathogen at enrollment72440667	Positive only for at least 1 penicillin-susceptible pathogen at enrollment72440668	Positive for at least 1 penicillin-nonsusceptible pathogen at enrollment72440667	Positive for at least 1 penicillin-nonsusceptible pathogen at enrollment72440668
	Penicillin-nonsusceptible isolate at a follow-up v	No penicillin-nonsusceptible isolate at a follow-u
Surgical Management	25
Non-Surgical Management	24
Surgical Management	12
Non-Surgical Management	11
Surgical Management	22
Non-Surgical Management	20
Surgical Management	11
Non-Surgical Management	15
Surgical Management	38
Non-Surgical Management	34
Surgical Management	5
Non-Surgical Management	9

Intervention	new adverse events reported (Number)
	Adverse Events at 3 months	Adverse Events at 6 months	Adverse Events at 12 months	Adverse Events at 24 months
DMEK	6	5	4	0
UT-DSAEK	4	4	1	0

Intervention	root mean square in micrometers (Mean)
	24 Months Anterior Cornea 4.0-mm	24 Months Posterior Cornea 4.0-mm	24 Months Anterior Cornea 6.0-mm	24 Months Posterior Cornea 6.0-mm
DMEK	0.211	0.086	0.679	0.260
DSAEK	0.215	0.155	0.707	0.450

Intervention	root mean square in micrometers (Mean)
	3 Months Anterior Cornea 4.0-mm	3 Months Posterior Cornea 4.0-mm	3 Months Anterior Cornea 6.0-mm	3 Months Posterior Cornea 6.0-mm	6 Months Anterior Cornea 4.0-mm	6 Months Posterior Cornea 4.0-mm	6 Months Anterior Cornea 6.0-mm	6 Months Posterior Cornea 6.0-mm	12 Months Anterior Cornea 4.0-mm	12 Months Posterior Cornea 4.0-mm	12 Months Anterior Cornea 6.0-mm	12 Months Posterior Cornea 6.0-mm
DMEK	0.288	0.116	0.829	0.346	0.243	0.095	0.724	0.288	0.241	0.098	0.723	0.284
UT-DSAEK	0.274	0.217	0.897	0.621	0.230	0.179	0.739	0.505	0.228	0.159	0.725	0.459

Intervention	cells/mm^2 (Mean)
	3 Months	6 Months	12 Months
DMEK	2037	1963	1855
UT-DSAEK	2114	2113	2070

Intervention	eyes (Number)
	Mild Interface Haze at 24 months	Moderate Interface Haze at 24 months	Severe Interface Haze at 24 months
DMEK	0	0	0
UT-DSAEK	0	1	0

Intervention	eyes (Number)
	Mild Interface Haze at 3 months	Moderate Interface Haze at 3 months	Severe Interface Haze at 3 months	Mild Interface Haze at 6 months	oderate Interface Haze at 6 months	Severe Interface Haze at 6 months	Mild Interface Haze at 12 months	oderate Interface Haze at 12 months	Severe Interface Haze at 12 months
DMEK	1	0	0	1	0	0	0	0	0
UT-DSAEK	2	0	0	2	1	0	0	0	0

Intervention	Participants (Count of Participants)
	Visit 272195661			Visit 272195662	Visit 372195662	Visit 372195661
	Clinical success	Clinical non-efficacy	Indefinite response
Nemonoxacin	164
Tavanic®	154
Nemonoxacin	4
Tavanic®	5
Nemonoxacin	1
Nemonoxacin	160
Tavanic®	151
Nemonoxacin	6
Tavanic®	7
Nemonoxacin	3
Tavanic®	8